Unnamed: 0 float64 0 700k | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher float64 | Author float64 | Article stringlengths 1 343k ⌀ | Lsa_summary stringlengths 48 53.9k ⌀ | Luhn_summary stringlengths 1 53.9k ⌀ | Textrank_summary stringlengths 1 53.9k ⌀ | Lexrank_summary stringlengths 1 53.9k ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|
25,600 | 2018-03-22 00:00:00 UTC | Health Care Sector Update for 03/22/2018: ABBV,SNGX,RETA,AVDL | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-03222018-abbvsngxretaavdl-2018-03-22 | null | null | Top Health Care Stocks
JNJ -2.87%
PFE -1.92%
ABT -2.21%
MRK -0.95%
AMGN -2.79%
Health care stocks fell into another deep hole today, including a more than 2.2% decline for the NYSE Health Care Index in recent trade. Also today, shares of health care companies in the S&P 500 were down over 2.8% as a group while the Nasd... | Among health care stocks moving on news: - AbbVie ( ABBV ) slumped Thursday, falling 15% on the way to a $95.52 a share session low, after the pharmaceuticals company said it won't seek accelerated approval for its Rova-T drug candidate as a potential treatment for patients with third-line relapsed or refractory small ... | "Although the results from the study were not what we hoped for, we look forward to receiving data from the ongoing phase 3 studies in the first- and second-line settings," chief scientific officer Mike Severino said, later adding AbbVie remains "committed to developing Rova-T for the treatment of patients with small c... | Among health care stocks moving on news: - AbbVie ( ABBV ) slumped Thursday, falling 15% on the way to a $95.52 a share session low, after the pharmaceuticals company said it won't seek accelerated approval for its Rova-T drug candidate as a potential treatment for patients with third-line relapsed or refractory small ... | Among health care stocks moving on news: - AbbVie ( ABBV ) slumped Thursday, falling 15% on the way to a $95.52 a share session low, after the pharmaceuticals company said it won't seek accelerated approval for its Rova-T drug candidate as a potential treatment for patients with third-line relapsed or refractory small ... |
25,601 | 2018-03-22 00:00:00 UTC | AbbVie (ABBV) Shares Cross 4% Yield Mark | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-shares-cross-4-yield-mark-2018-03-22 | null | null | Looking at the universe of stocks we cover at Dividend Channel , in trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 4% mark based on its quarterly dividend (annualized to $3.84), with the stock changing hands as low as $95.52 on the day. Dividends are particularly important for investor... | Looking at the universe of stocks we cover at Dividend Channel , in trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 4% mark based on its quarterly dividend (annualized to $3.84), with the stock changing hands as low as $95.52 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, ... | Looking at the universe of stocks we cover at Dividend Channel , in trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 4% mark based on its quarterly dividend (annualized to $3.84), with the stock changing hands as low as $95.52 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, ... | Looking at the universe of stocks we cover at Dividend Channel , in trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 4% mark based on its quarterly dividend (annualized to $3.84), with the stock changing hands as low as $95.52 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, ... | AbbVie Inc (Symbol: ABBV) is an S&P 500 company, giving it special status as one of the large-cap companies making up the S&P 500 Index. Looking at the universe of stocks we cover at Dividend Channel , in trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 4% mark based on its quarterly div... |
25,602 | 2018-03-22 00:00:00 UTC | What Happened in the Stock Market Today | ABBV | https://www.nasdaq.com/articles/what-happened-stock-market-today-2018-03-22 | null | null | Worries over trade had stock investors on the run Thursday. The Dow Jones Industrial Average (DJINDICES: ^DJI) and the S&P 500 (SNPINDEX: ^GSPC) closed near their lows for the day with large losses.
Today's stock market
Data source: Yahoo! Finance.
The sole bright spot in the market was the utility sector, as bonds ral... | The drug came to AbbVie following its pricey $9.8 billion 2016 purchase of Stemcentryx, and the company has had high expectations for Rova-T despite some skepticism by observers and a low response rate in a phase 1 trial. (NYSE: GES) reported strong holiday sales and AbbVie (NYSE: ABBV) announced disappointing results ... | (NYSE: GES) reported strong holiday sales and AbbVie (NYSE: ABBV) announced disappointing results from a trial of an important pipeline drug. AbbVie sinks on weak cancer trial results Shares of pharma giant AbbVie plummeted 12.8% after the company announced disappointing results from a cancer drug trial and stated that... | AbbVie sinks on weak cancer trial results Shares of pharma giant AbbVie plummeted 12.8% after the company announced disappointing results from a cancer drug trial and stated that it will not seek accelerated approval of the drug, meaning that AbbVie will likely not see revenue from it in 2018, as previously expected. (... | AbbVie sinks on weak cancer trial results Shares of pharma giant AbbVie plummeted 12.8% after the company announced disappointing results from a cancer drug trial and stated that it will not seek accelerated approval of the drug, meaning that AbbVie will likely not see revenue from it in 2018, as previously expected. (... |
25,603 | 2018-03-21 00:00:00 UTC | iShares Core S&P Total U.S. Stock Market ETF Experiences Big Inflow | ABBV | https://www.nasdaq.com/articles/ishares-core-sp-total-us-stock-market-etf-experiences-big-inflow-2018-03-21 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core S&P Total U.S. Stock Market ETF (Symbol: ITOT) where we have detected an approximate $81.1 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (... | Among the largest underlying components of ITOT, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.4%, Oracle Corp (Symbol: ORCL) is up about 0.6%, and Texas Instruments Inc. (Symbol: TXN) is up by about 0.2%. For a complete list of holdings, visit the ITOT Holdings page » The chart below shows the one year pr... | Among the largest underlying components of ITOT, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.4%, Oracle Corp (Symbol: ORCL) is up about 0.6%, and Texas Instruments Inc. (Symbol: TXN) is up by about 0.2%. For a complete list of holdings, visit the ITOT Holdings page » The chart below shows the one year pr... | Among the largest underlying components of ITOT, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.4%, Oracle Corp (Symbol: ORCL) is up about 0.6%, and Texas Instruments Inc. (Symbol: TXN) is up by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF ... | Among the largest underlying components of ITOT, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.4%, Oracle Corp (Symbol: ORCL) is up about 0.6%, and Texas Instruments Inc. (Symbol: TXN) is up by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF ... |
25,604 | 2018-03-20 00:00:00 UTC | 3 Healthcare Stocks Hedge Funds Like the Most | ABBV | https://www.nasdaq.com/articles/3-healthcare-stocks-hedge-funds-most-2018-03-20 | null | null | Healthcare represents nearly one-fifth the U.S. economy. And demand for healthcare products and services is growing. You might think that there would be plenty of healthcare stocks are popular with hedge funds.
Personal finance website WalletHub ranked the top 25 most popular stocks owned by hedge funds in the fourth q... | One big factor driving AbbVie stock higher is that its top-selling drug Humira appears to be safe from biosimilar competition in the U.S., thanks to a deal made with Amgen last year. Interestingly, only three were healthcare stocks -- UnitedHealth Group (NYSE: UNH) , Johnson & Johnson (NYSE: JNJ) , and AbbVie (NYSE: AB... | Interestingly, only three were healthcare stocks -- UnitedHealth Group (NYSE: UNH) , Johnson & Johnson (NYSE: JNJ) , and AbbVie (NYSE: ABBV) . AbbVie AbbVie took the No. Buying more shares in AbbVie was a smart thing to do. | Interestingly, only three were healthcare stocks -- UnitedHealth Group (NYSE: UNH) , Johnson & Johnson (NYSE: JNJ) , and AbbVie (NYSE: ABBV) . If you're focused on growth, AbbVie claims the best growth prospects of the healthcare stocks ranked in the top 25 most popular stocks for hedge funds. AbbVie AbbVie took the No... | AbbVie AbbVie took the No. Interestingly, only three were healthcare stocks -- UnitedHealth Group (NYSE: UNH) , Johnson & Johnson (NYSE: JNJ) , and AbbVie (NYSE: ABBV) . Buying more shares in AbbVie was a smart thing to do. |
25,605 | 2018-03-19 00:00:00 UTC | J&J Gets $2.1B Offer for LifeScan Diabetes Device Unit | ABBV | https://www.nasdaq.com/articles/jj-gets-%242.1b-offer-for-lifescan-diabetes-device-unit-2018-03-19 | null | null | Johnson & JohnsonJNJ announced that it has received a binding offer of approximately $2.1 billion from a private equity firm, Platinum Equity, for its LifeScan diabetes device unit. The LifeScan unit makes blood glucose monitoring products and generated revenues of $1.5 billion last year.
J&J stock has declined 3.8% th... | Better-ranked large-cap pharma stocks include AbbVie, Inc. ABBV and Pfizer Inc. PFE , both with a Zacks Rank #2 (Buy). AbbVie's earnings per share estimates have moved up 14% for 2018 and almost 10% for 2019 in the last 60 days. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johns... | Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Medtronic Public Limited Company (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. Better-ranked large-cap pharma s... | Better-ranked large-cap pharma stocks include AbbVie, Inc. ABBV and Pfizer Inc. PFE , both with a Zacks Rank #2 (Buy). Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Medtronic Public Limited C... | Better-ranked large-cap pharma stocks include AbbVie, Inc. ABBV and Pfizer Inc. PFE , both with a Zacks Rank #2 (Buy). AbbVie's earnings per share estimates have moved up 14% for 2018 and almost 10% for 2019 in the last 60 days. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johns... |
25,606 | 2018-03-16 00:00:00 UTC | Why Multiple Sclerosis is a Promising but Risky Space? | ABBV | https://www.nasdaq.com/articles/why-multiple-sclerosis-is-a-promising-but-risky-space-2018-03-16 | null | null | The Multiple Sclerosis (MS) space hit the headlines once again following biotech bigwig, Biogen BIIB and partner AbbVie's ABBV decision to withdraw their jointly owned MS drug, Zinbryta voluntarily on a worldwide basis due to risk of liver injury. Both companies decided to withdraw the drug on grounds of the complex an... | The Multiple Sclerosis (MS) space hit the headlines once again following biotech bigwig, Biogen BIIB and partner AbbVie's ABBV decision to withdraw their jointly owned MS drug, Zinbryta voluntarily on a worldwide basis due to risk of liver injury. Click to get this free report Novartis AG (NVS): Free Stock Analysis Rep... | Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report To read this article on ... | The Multiple Sclerosis (MS) space hit the headlines once again following biotech bigwig, Biogen BIIB and partner AbbVie's ABBV decision to withdraw their jointly owned MS drug, Zinbryta voluntarily on a worldwide basis due to risk of liver injury. Click to get this free report Novartis AG (NVS): Free Stock Analysis Rep... | The Multiple Sclerosis (MS) space hit the headlines once again following biotech bigwig, Biogen BIIB and partner AbbVie's ABBV decision to withdraw their jointly owned MS drug, Zinbryta voluntarily on a worldwide basis due to risk of liver injury. Click to get this free report Novartis AG (NVS): Free Stock Analysis Rep... |
25,607 | 2018-03-16 00:00:00 UTC | Pharma Stock Roundup: ABBV's Elagolix Meets Study Goal, MRK's Keytruda in Focus | ABBV | https://www.nasdaq.com/articles/pharma-stock-roundup%3A-abbvs-elagolix-meets-study-goal-mrks-keytruda-in-focus-2018-03-16 | null | null | This week was a relatively light one as far as developments in the pharma sector were concerned. The key highlights were priority review for Merck's MRK Keytruda for advanced cervical cancer, delay in final data from AstraZeneca's AZN key lung cancer study, success of AbbVie's ABBV another late stage study and breakthr... | The key highlights were priority review for Merck's MRK Keytruda for advanced cervical cancer, delay in final data from AstraZeneca's AZN key lung cancer study, success of AbbVie's ABBV another late stage study and breakthrough therapy designation for J&J's JNJ cancer candidate. (Read More: Merck's Keytruda Gets Priori... | The key highlights were priority review for Merck's MRK Keytruda for advanced cervical cancer, delay in final data from AstraZeneca's AZN key lung cancer study, success of AbbVie's ABBV another late stage study and breakthrough therapy designation for J&J's JNJ cancer candidate. (Read More: Abbvie's Uterine Fibrosis Ca... | The key highlights were priority review for Merck's MRK Keytruda for advanced cervical cancer, delay in final data from AstraZeneca's AZN key lung cancer study, success of AbbVie's ABBV another late stage study and breakthrough therapy designation for J&J's JNJ cancer candidate. (Read More: Merck's Keytruda Gets Priori... | (Read More: Merck's Keytruda Gets Priority Review for Cervical Cancer ) AbbVie Second Late-Stage Study on Elagolix Meets Endpoints: AbbVie and Neurocrine Biosciences' second of the two pivotal phase III studies on pipeline candidate, elagolix met the primary endpoint. The key highlights were priority review for Merck's... |
25,608 | 2018-03-16 00:00:00 UTC | 5 Must-See Quotes From AbbVie's Management | ABBV | https://www.nasdaq.com/articles/5-must-see-quotes-abbvies-management-2018-03-16 | null | null | What's the best big pharma stock on the market right now? The prize has to go to AbbVie (NYSE: ABBV) . The stock soared 54% last year and is up more than 20% so far in 2018.
Everything seems to be going AbbVie's way lately, which makes it really easy for the company's executives when they field questions at major confe... | That was the case for AbbVie CFO Bill Chase and Vice President of Scientific Affairs Scott Brun at the Barclays Global Healthcare Conference on Thursday. AbbVie CFO Bill Chase said that the Amgen agreement and positive decisions by the U.S. Patent and Trademark Office have helped the market "come to the conclusion that... | AbbVie CFO Bill Chase said that the Amgen agreement and positive decisions by the U.S. Patent and Trademark Office have helped the market "come to the conclusion that this product [Humira] is durable." AbbVie launched HCV drug Viekira in 2016. The prize has to go to AbbVie (NYSE: ABBV) . | You're "not going to see anything catastrophic" with Humira Without question, the most important factor driving AbbVie stock higher last year was the removal of uncertainty about the fate of Humira. AbbVie CFO Bill Chase said that the Amgen agreement and positive decisions by the U.S. Patent and Trademark Office have h... | Everything seems to be going AbbVie's way lately, which makes it really easy for the company's executives when they field questions at major conferences. AbbVie launched HCV drug Viekira in 2016. "Don't expect anything major" when it comes to deals Will AbbVie make more acquisitions in 2018? |
25,609 | 2018-03-15 00:00:00 UTC | 7 Things Vertex Pharmaceuticals' CEO Just Said That Will Probably Make You Want to Buy the Stock | ABBV | https://www.nasdaq.com/articles/7-things-vertex-pharmaceuticals-ceo-just-said-will-probably-make-you-want-buy-stock-2018 | null | null | Vertex Pharmaceuticals (NASDAQ: VRTX) achieved something in 2017 that few stocks did: It more than doubled. At the beginning of this year, I picked Vertex as one of the top big biotech stocks to buy . That pick has looked good so far. Vertex is off to a great start in 2018, with a year-to-date gain of more than 15%.
Bu... | But with CF patients resistant to switching from a therapy that works for them, a similar triple-drug combo from Galapagos and AbbVie could have a hard time gaining market traction following Vertex's launch. Galapagos (NASDAQ: GLPG) and AbbVie (NYSE: ABBV) are developing a triple-drug combo as well. *Stock Advisor retu... | Galapagos (NASDAQ: GLPG) and AbbVie (NYSE: ABBV) are developing a triple-drug combo as well. But with CF patients resistant to switching from a therapy that works for them, a similar triple-drug combo from Galapagos and AbbVie could have a hard time gaining market traction following Vertex's launch. *Stock Advisor retu... | But with CF patients resistant to switching from a therapy that works for them, a similar triple-drug combo from Galapagos and AbbVie could have a hard time gaining market traction following Vertex's launch. Galapagos (NASDAQ: GLPG) and AbbVie (NYSE: ABBV) are developing a triple-drug combo as well. *Stock Advisor retu... | Galapagos (NASDAQ: GLPG) and AbbVie (NYSE: ABBV) are developing a triple-drug combo as well. But with CF patients resistant to switching from a therapy that works for them, a similar triple-drug combo from Galapagos and AbbVie could have a hard time gaining market traction following Vertex's launch. *Stock Advisor retu... |
25,610 | 2018-03-15 00:00:00 UTC | Zacks Market Edge Highlights: Scotts Miracle-Gro, GW Pharmaceuticals, Innovative Industrial Properties and AbbVie | ABBV | https://www.nasdaq.com/articles/zacks-market-edge-highlights%3A-scotts-miracle-gro-gw-pharmaceuticals-innovative-industrial | null | null | For Immediate Release
Chicago, IL - March 15, 2018 - Zacks Market Edge is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec. Every week, Tracey will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. To listen to the podcast, click here: ( h... | AbbVieABBV is a large cap US biopharmaceutical company which just happens to be one of the first with an FDA approved cannabis-based drug, Marinol, on the market. AbbVie is expected to grow earnings by 33% in 2018 yet trades with a forward P/E of just 15.8. Click to get this free report AbbVie Inc. (ABBV): Free Stock A... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report GW Pharmaceuticals PLC (GWPH): Free Stock Analysis Report Scotts Miracle-Gro Company (The) (SMG): Free Stock Analysis Report Innovative Industrial Properties, Inc. (IIPR): Free Stock Analysis Report To read this article on Zacks.com click here... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report GW Pharmaceuticals PLC (GWPH): Free Stock Analysis Report Scotts Miracle-Gro Company (The) (SMG): Free Stock Analysis Report Innovative Industrial Properties, Inc. (IIPR): Free Stock Analysis Report To read this article on Zacks.com click here... | AbbVieABBV is a large cap US biopharmaceutical company which just happens to be one of the first with an FDA approved cannabis-based drug, Marinol, on the market. AbbVie is expected to grow earnings by 33% in 2018 yet trades with a forward P/E of just 15.8. Click to get this free report AbbVie Inc. (ABBV): Free Stock A... |
25,611 | 2018-03-14 00:00:00 UTC | AbbVie's Uterine Fibroids Candidate Succeeds in Phase III | ABBV | https://www.nasdaq.com/articles/abbvies-uterine-fibroids-candidate-succeeds-in-phase-iii-2018-03-14 | null | null | AbbVieABBV and partner Neurocrine Biosciences announced that the second of the two pivotal phase III studies evaluating its pipeline candidate, elagolix uterine fibroids, met the primary endpoint. AbbVie is looking to get elagolix approved as an oral medicine for reducing heavy menstrual bleeding in premenopausal women... | AbbVieABBV and partner Neurocrine Biosciences announced that the second of the two pivotal phase III studies evaluating its pipeline candidate, elagolix uterine fibroids, met the primary endpoint. AbbVie is looking to get elagolix approved as an oral medicine for reducing heavy menstrual bleeding in premenopausal women... | AbbVieABBV and partner Neurocrine Biosciences announced that the second of the two pivotal phase III studies evaluating its pipeline candidate, elagolix uterine fibroids, met the primary endpoint. AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank & Key Picks AbbVie carries a Zacks Rank #2 (Buy). Click ... | AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank & Key Picks AbbVie carries a Zacks Rank #2 (Buy). Click to get this free report Allergan plc (AGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Ligand Pharm... | AbbVieABBV and partner Neurocrine Biosciences announced that the second of the two pivotal phase III studies evaluating its pipeline candidate, elagolix uterine fibroids, met the primary endpoint. AbbVie's shares have increased more than 1% on Mar 13, following the news release. AbbVie is looking to get elagolix approv... |
25,612 | 2018-03-14 00:00:00 UTC | The Best Marijuana Stocks Right Now | ABBV | https://www.nasdaq.com/articles/best-marijuana-stocks-right-now-2018-03-14 | null | null | (0: 20 ) - Where To Invest With Pot Stocks
(2: 30 ) - 2017 Stock Pick Update: ACBFF, GWPH, SMG, IIPR
(8: 00 ) - Top Picks For 2018: ABBV, CRON, STZ, INSY, CARA
(16: 10 ) - Risk and Rewards of Buying Pot Stocks
(19: 40 ) - Episode Roundup: Podcast@Zacks.com
It is getting easier to buy stocks that do business in the emer... | (0: 20 ) - Where To Invest With Pot Stocks (2: 30 ) - 2017 Stock Pick Update: ACBFF, GWPH, SMG, IIPR (8: 00 ) - Top Picks For 2018: ABBV, CRON, STZ, INSY, CARA (16: 10 ) - Risk and Rewards of Buying Pot Stocks (19: 40 ) - Episode Roundup: Podcast@Zacks.com It is getting easier to buy stocks that do business in the emer... | (0: 20 ) - Where To Invest With Pot Stocks (2: 30 ) - 2017 Stock Pick Update: ACBFF, GWPH, SMG, IIPR (8: 00 ) - Top Picks For 2018: ABBV, CRON, STZ, INSY, CARA (16: 10 ) - Risk and Rewards of Buying Pot Stocks (19: 40 ) - Episode Roundup: Podcast@Zacks.com It is getting easier to buy stocks that do business in the emer... | (0: 20 ) - Where To Invest With Pot Stocks (2: 30 ) - 2017 Stock Pick Update: ACBFF, GWPH, SMG, IIPR (8: 00 ) - Top Picks For 2018: ABBV, CRON, STZ, INSY, CARA (16: 10 ) - Risk and Rewards of Buying Pot Stocks (19: 40 ) - Episode Roundup: Podcast@Zacks.com It is getting easier to buy stocks that do business in the emer... | AbbVieABBV is a large cap US biopharmaceutical company which just happens to be one of the first with an FDA approved cannabis-based drug, Marinol, on the market. (0: 20 ) - Where To Invest With Pot Stocks (2: 30 ) - 2017 Stock Pick Update: ACBFF, GWPH, SMG, IIPR (8: 00 ) - Top Picks For 2018: ABBV, CRON, STZ, INSY, CA... |
25,613 | 2018-03-13 00:00:00 UTC | VHT, ABBV, BMY, DHR: ETF Outflow Alert | ABBV | https://www.nasdaq.com/articles/vht-abbv-bmy-dhr-etf-outflow-alert-2018-03-13 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Health Care ETF (Symbol: VHT) where we have detected an approximate $48.7 million dollar outflow -- that's a 0.6% decrease week over week (from 46,154,984 to 45,855,745). Among the... | Among the largest underlying components of VHT, in trading today AbbVie Inc (Symbol: ABBV) is up about 2.3%, Bristol-Myers Squibb Co. (Symbol: BMY) is up about 0.3%, and Danaher Corp (Symbol: DHR) is higher by about 0.6%. For a complete list of holdings, visit the VHT Holdings page » The chart below shows the one year ... | Among the largest underlying components of VHT, in trading today AbbVie Inc (Symbol: ABBV) is up about 2.3%, Bristol-Myers Squibb Co. (Symbol: BMY) is up about 0.3%, and Danaher Corp (Symbol: DHR) is higher by about 0.6%. For a complete list of holdings, visit the VHT Holdings page » The chart below shows the one year ... | Among the largest underlying components of VHT, in trading today AbbVie Inc (Symbol: ABBV) is up about 2.3%, Bristol-Myers Squibb Co. (Symbol: BMY) is up about 0.3%, and Danaher Corp (Symbol: DHR) is higher by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at E... | Among the largest underlying components of VHT, in trading today AbbVie Inc (Symbol: ABBV) is up about 2.3%, Bristol-Myers Squibb Co. (Symbol: BMY) is up about 0.3%, and Danaher Corp (Symbol: DHR) is higher by about 0.6%. For a complete list of holdings, visit the VHT Holdings page » The chart below shows the one year ... |
25,614 | 2018-03-13 00:00:00 UTC | Broadcom Can't Buy Qualcomm, But You Can | ABBV | https://www.nasdaq.com/articles/broadcom-cant-buy-qualcomm-you-can-2018-03-13 | null | null | For those of us not obsessed with porn stars and Russia investigations, the big news yesterday was the intervention by the White House to block the proposed takeover of Qualcomm (QCOM) by Broadcom (AVGO). The hostile takeover bid had, as these things tend to do, become extremely contentious, but is now over due to a ru... | As an example, back in 2014 when the pharmaceutical industry was in an M&A frenzy and inversions were all the rage, a proposed takeover of the U.K. firm Shire PLC (SHPG) by AbbVie (ABBV) fell apart. As a result, SHPG dropped dramatically, but, as I pointed out at the time, the value beyond the benefits of inversion tha... | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. As an example, back in 2014 when the pharmaceutical industry was in an M&A frenzy and inversions were all the rage, a proposed takeover of the U.K. firm Shire PLC (SHPG) by AbbVie (ABBV)... | As an example, back in 2014 when the pharmaceutical industry was in an M&A frenzy and inversions were all the rage, a proposed takeover of the U.K. firm Shire PLC (SHPG) by AbbVie (ABBV) fell apart. As a result, SHPG dropped dramatically, but, as I pointed out at the time, the value beyond the benefits of inversion tha... | As an example, back in 2014 when the pharmaceutical industry was in an M&A frenzy and inversions were all the rage, a proposed takeover of the U.K. firm Shire PLC (SHPG) by AbbVie (ABBV) fell apart. As a result, SHPG dropped dramatically, but, as I pointed out at the time, the value beyond the benefits of inversion tha... |
25,615 | 2018-03-13 00:00:00 UTC | Health Care Sector Update for 03/13/2018: ABBV, BLCM, EPZM, MRK | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-03132018-abbv-blcm-epzm-mrk-2018-03-13 | null | null | Top Health-care stocks:
JNJ: +0.3%
PFE: +0.3%
ABT: flat
MRK: flat
AMGN: flat
Health care shares were mostly higher ahead of the bell on Tuesday.
Expected movers:
- Bellicum Pharma ( BLCM ): reports low rates of cancer recurrence in AML patients treated with BPX-501
- AbbVie ( ABBV ): phase 3 study of Elagolix in women ... | Expected movers: - Bellicum Pharma ( BLCM ): reports low rates of cancer recurrence in AML patients treated with BPX-501 - AbbVie ( ABBV ): phase 3 study of Elagolix in women with uterine fibroids meets primary endpoint - Epizyme ( EPZM ): reports narrower-than-expected Q4 loss Other news: - Merck ( MRK ): US FDA grant... | Expected movers: - Bellicum Pharma ( BLCM ): reports low rates of cancer recurrence in AML patients treated with BPX-501 - AbbVie ( ABBV ): phase 3 study of Elagolix in women with uterine fibroids meets primary endpoint - Epizyme ( EPZM ): reports narrower-than-expected Q4 loss Other news: - Merck ( MRK ): US FDA grant... | Expected movers: - Bellicum Pharma ( BLCM ): reports low rates of cancer recurrence in AML patients treated with BPX-501 - AbbVie ( ABBV ): phase 3 study of Elagolix in women with uterine fibroids meets primary endpoint - Epizyme ( EPZM ): reports narrower-than-expected Q4 loss Other news: - Merck ( MRK ): US FDA grant... | Expected movers: - Bellicum Pharma ( BLCM ): reports low rates of cancer recurrence in AML patients treated with BPX-501 - AbbVie ( ABBV ): phase 3 study of Elagolix in women with uterine fibroids meets primary endpoint - Epizyme ( EPZM ): reports narrower-than-expected Q4 loss Other news: - Merck ( MRK ): US FDA grant... |
25,616 | 2018-03-13 00:00:00 UTC | Health Care Sector Update for 03/13/2018: ABBV,NBIX,EPZM,BLCM,MRK | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-03132018-abbvnbixepzmblcmmrk-2018-03-13 | null | null | Top Health Care Stocks
JNJ +1.41%
PFE +0.29%
ABT -0.72%
MRK -0.24%
AMGN +0.16%
Health care stocks still were ending on positive ground Tuesday, with the NYSE Health Care Index hanging on to a nearly 0.1% gain in recent trade. Also today, shares of health care companies in the S&P 500 were up a little more than 0.1% as ... | Among health care stocks moving on news: + AbbVie ( ABBV ) was higher in late Tuesday trading, climbing almost 3% to a session high of $121.45 a share, after the biopharmaceuticals company, together with Neurocrine Biosciences ( NBIX ), said its elagolix drug candidate met its primary endpoint during the second of two ... | Among health care stocks moving on news: + AbbVie ( ABBV ) was higher in late Tuesday trading, climbing almost 3% to a session high of $121.45 a share, after the biopharmaceuticals company, together with Neurocrine Biosciences ( NBIX ), said its elagolix drug candidate met its primary endpoint during the second of two ... | Among health care stocks moving on news: + AbbVie ( ABBV ) was higher in late Tuesday trading, climbing almost 3% to a session high of $121.45 a share, after the biopharmaceuticals company, together with Neurocrine Biosciences ( NBIX ), said its elagolix drug candidate met its primary endpoint during the second of two ... | Among health care stocks moving on news: + AbbVie ( ABBV ) was higher in late Tuesday trading, climbing almost 3% to a session high of $121.45 a share, after the biopharmaceuticals company, together with Neurocrine Biosciences ( NBIX ), said its elagolix drug candidate met its primary endpoint during the second of two ... |
25,617 | 2018-03-13 00:00:00 UTC | Is This AbbVie's Next Blockbuster Drug? | ABBV | https://www.nasdaq.com/articles/abbvies-next-blockbuster-drug-2018-03-13 | null | null | AbbVie 's (NYSE: ABBV) elagolix has taken another leap toward billion-dollar blockbuster sales status. An FDA decision on elagolix use in endometriosis patients is anticipated soon, and on Tuesday, AbbVie management unveiled data from trials evaluating it in uterine fibroids. If the FDA give the go-ahead for elagoix in... | Awaiting a decision AbbVie acquired global rights to elagolix from Neurocrine Biosciences (NASDAQ: NBIX) in 2010, when it had just successfully completed a phase 2b trial in endometriosis. Tapping into a major market opportunity AbbVie is putting serious weight into its efforts to develop new drugs that could cushion i... | In September 2017, AbbVie submitted elagolix for FDA approval following phase 3 trials showing it reduces three types of endometriosis-associated pain: daily menstrual pelvic pain, non-menstrual pelvic pain, and painful intercourse. AbbVie 's (NYSE: ABBV) elagolix has taken another leap toward billion-dollar blockbuste... | An FDA decision on elagolix use in endometriosis patients is anticipated soon, and on Tuesday, AbbVie management unveiled data from trials evaluating it in uterine fibroids. In September 2017, AbbVie submitted elagolix for FDA approval following phase 3 trials showing it reduces three types of endometriosis-associated ... | An FDA decision on elagolix use in endometriosis patients is anticipated soon, and on Tuesday, AbbVie management unveiled data from trials evaluating it in uterine fibroids. AbbVie 's (NYSE: ABBV) elagolix has taken another leap toward billion-dollar blockbuster sales status. Awaiting a decision AbbVie acquired global ... |
25,618 | 2018-03-12 00:00:00 UTC | The 1 Big Risk That Every Drugmaker Fears | ABBV | https://www.nasdaq.com/articles/1-big-risk-every-drugmaker-fears-2018-03-12 | null | null | Drug safety trumps efficacy, regardless of how successful a drug is in treating a condition. This makes picking the right drug target and drug design critical.
In this clip from The Motley Fool's Industry Focus: Healthcare podcast, host Kristine Harjes and contributor Todd Campbell discuss how safety plays a role in co... | In this clip from The Motley Fool's Industry Focus: Healthcare podcast, host Kristine Harjes and contributor Todd Campbell discuss how safety plays a role in corporate strategy and competitive battles using Gilead Sciences ' (NASDAQ: GILD) face-off against Johnson & Johnson (NYSE: JNJ) and AbbVie Inc . (NYSE: ABBV) in ... | In this clip from The Motley Fool's Industry Focus: Healthcare podcast, host Kristine Harjes and contributor Todd Campbell discuss how safety plays a role in corporate strategy and competitive battles using Gilead Sciences ' (NASDAQ: GILD) face-off against Johnson & Johnson (NYSE: JNJ) and AbbVie Inc . (NYSE: ABBV) in ... | In this clip from The Motley Fool's Industry Focus: Healthcare podcast, host Kristine Harjes and contributor Todd Campbell discuss how safety plays a role in corporate strategy and competitive battles using Gilead Sciences ' (NASDAQ: GILD) face-off against Johnson & Johnson (NYSE: JNJ) and AbbVie Inc . (NYSE: ABBV) in ... | That won approval in 2004, around the same time as another competing drug in the same indication from Johnson & Johnson and AbbVie, which we've talked about on the show before, called Imbruvica. In this clip from The Motley Fool's Industry Focus: Healthcare podcast, host Kristine Harjes and contributor Todd Campbell di... |
25,619 | 2018-03-12 00:00:00 UTC | How Pricing Can Be Vital to a Drugmaker's Profitability | ABBV | https://www.nasdaq.com/articles/how-pricing-can-be-vital-drugmakers-profitability-2018-03-12 | null | null | Game-changing efficacy and safety will undeniably allow any drugmaker to dominate an indication, but when drugs match up nicely to each other, price can be the key differentiator.
In this clip from The Motley Fool's Industry Focus: Healthcare , host Kristine Harjes and Motley Fool contributor Todd Campbell discuss pric... | In this clip from The Motley Fool's Industry Focus: Healthcare , host Kristine Harjes and Motley Fool contributor Todd Campbell discuss pricing strategies used by companies to rack up revenue for investors using the hepatitis C brawl between Gilead Sciences (NASDAQ: GILD) and AbbVie (NYSE: ABBV) as an example. Todd Cam... | In this clip from The Motley Fool's Industry Focus: Healthcare , host Kristine Harjes and Motley Fool contributor Todd Campbell discuss pricing strategies used by companies to rack up revenue for investors using the hepatitis C brawl between Gilead Sciences (NASDAQ: GILD) and AbbVie (NYSE: ABBV) as an example. Todd Cam... | In this clip from The Motley Fool's Industry Focus: Healthcare , host Kristine Harjes and Motley Fool contributor Todd Campbell discuss pricing strategies used by companies to rack up revenue for investors using the hepatitis C brawl between Gilead Sciences (NASDAQ: GILD) and AbbVie (NYSE: ABBV) as an example. And then... | And that's why the Viekira Pak, which was AbbVie's first hepatitis C drug, when that came out, I think it won approval at the end of 2014, maybe launched in 2015. And then, fast-forward to 2017 with AbbVie's most recent drug that just launched, and I think that drug is priced at less than $30,000 for an eight-week cour... |
25,620 | 2018-03-10 00:00:00 UTC | 3 Dividend Stocks That Are Perfect for Retirement | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-are-perfect-retirement-2018-03-10 | null | null | If you're retired, you want to own dividend stocks that have long track records of consistent, growing dividends. No retiree wants to take undue risk on dividend stocks that haven't yet proven themselves.
Here's why three of our Foolish investors think AbbVie (NYSE: ABBV) , General Mills (NYSE: GIS) , and Enbridge (NYS... | Here's why three of our Foolish investors think AbbVie (NYSE: ABBV) , General Mills (NYSE: GIS) , and Enbridge (NYSE: ENB) are dividend stocks that are perfect for retirement. Taking the risk out of drug discovery Rich Duprey(AbbVie): Drugmaker AbbVie still counts on rheumatoid arthritis therapy Humira for the bulk of ... | Here's why three of our Foolish investors think AbbVie (NYSE: ABBV) , General Mills (NYSE: GIS) , and Enbridge (NYSE: ENB) are dividend stocks that are perfect for retirement. Taking the risk out of drug discovery Rich Duprey(AbbVie): Drugmaker AbbVie still counts on rheumatoid arthritis therapy Humira for the bulk of ... | Here's why three of our Foolish investors think AbbVie (NYSE: ABBV) , General Mills (NYSE: GIS) , and Enbridge (NYSE: ENB) are dividend stocks that are perfect for retirement. Taking the risk out of drug discovery Rich Duprey(AbbVie): Drugmaker AbbVie still counts on rheumatoid arthritis therapy Humira for the bulk of ... | Here's why three of our Foolish investors think AbbVie (NYSE: ABBV) , General Mills (NYSE: GIS) , and Enbridge (NYSE: ENB) are dividend stocks that are perfect for retirement. Taking the risk out of drug discovery Rich Duprey(AbbVie): Drugmaker AbbVie still counts on rheumatoid arthritis therapy Humira for the bulk of ... |
25,621 | 2018-03-10 00:00:00 UTC | How Biopharmas Battle for Billions | ABBV | https://www.nasdaq.com/articles/how-biopharmas-battle-billions-2018-03-10 | null | null | Billion-dollar blockbuster status is the holy grail of drug development; however, 90% of clinical trials fail and only a few drugs achieve this milestone. How do drugmakers overcome the odds?
In this episode of The Motley Fool's Industry Focus: Healthcare , host Kristine Harjes is joined by Motley Fool contributor Todd... | In this episode of The Motley Fool's Industry Focus: Healthcare , host Kristine Harjes is joined by Motley Fool contributor Todd Campbell to discuss how efficacy, safety, price, and convenience affect sales at top companies, including Gilead Sciences (NASDAQ: GILD) , AbbVie (NYSE: ABBV) , and Bristol-Myers Squibb (NYSE... | In this episode of The Motley Fool's Industry Focus: Healthcare , host Kristine Harjes is joined by Motley Fool contributor Todd Campbell to discuss how efficacy, safety, price, and convenience affect sales at top companies, including Gilead Sciences (NASDAQ: GILD) , AbbVie (NYSE: ABBV) , and Bristol-Myers Squibb (NYSE... | In this episode of The Motley Fool's Industry Focus: Healthcare , host Kristine Harjes is joined by Motley Fool contributor Todd Campbell to discuss how efficacy, safety, price, and convenience affect sales at top companies, including Gilead Sciences (NASDAQ: GILD) , AbbVie (NYSE: ABBV) , and Bristol-Myers Squibb (NYSE... | In this episode of The Motley Fool's Industry Focus: Healthcare , host Kristine Harjes is joined by Motley Fool contributor Todd Campbell to discuss how efficacy, safety, price, and convenience affect sales at top companies, including Gilead Sciences (NASDAQ: GILD) , AbbVie (NYSE: ABBV) , and Bristol-Myers Squibb (NYSE... |
25,622 | 2018-03-09 00:00:00 UTC | Zacks Value Investor Highlights: Diageo, Mylan, Sony, AbbVie and Walgreens | ABBV | https://www.nasdaq.com/articles/zacks-value-investor-highlights%3A-diageo-mylan-sony-abbvie-and-walgreens-2018-03-09 | null | null | For Immediate Release
Chicago, IL - March 9, 2018 - Zacks Value Investor is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec. Every week, Tracey will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. To listen to the podcast, click here:
(... | AbbVieABBV is a rare growth and value stock. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Sony Corp Ord (SNE): Free Stock Analysis Report Diageo PLC (DEO): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis Re... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Sony Corp Ord (SNE): Free Stock Analysis Report Diageo PLC (DEO): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis Report To read this article on Zacks.com click ... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Sony Corp Ord (SNE): Free Stock Analysis Report Diageo PLC (DEO): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis Report To read this article on Zacks.com click ... | AbbVieABBV is a rare growth and value stock. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Sony Corp Ord (SNE): Free Stock Analysis Report Diageo PLC (DEO): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis Re... |
25,623 | 2018-03-09 00:00:00 UTC | Is Big Pharma Using Corporate Tax Savings to Lower Drug Costs? | ABBV | https://www.nasdaq.com/articles/is-big-pharma-using-corporate-tax-savings-to-lower-drug-costs-2018-03-09 | null | null | With the passing of the new tax bill, the corporate tax rate has come down from 35% to 21% which is likely to boosts profit margins. Moreover, the cash repatriation window allowed in the bill will help companies to bring in cash stashed in foreign locations at a one-time tax rate of 10%, leaving these companies with ex... | The Senator has sent letters to CEOs of Pfizer Inc. PFE , Merck & Co., Inc. MRK , Johnson & Johnson JNJ , AbbVie Inc. ABBV and Abbott Laboratories ABT to provide the details of how they intend to utilize major savings from the tax overhaul. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Joh... | The Senator has sent letters to CEOs of Pfizer Inc. PFE , Merck & Co., Inc. MRK , Johnson & Johnson JNJ , AbbVie Inc. ABBV and Abbott Laboratories ABT to provide the details of how they intend to utilize major savings from the tax overhaul. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Joh... | Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com c... | The Senator has sent letters to CEOs of Pfizer Inc. PFE , Merck & Co., Inc. MRK , Johnson & Johnson JNJ , AbbVie Inc. ABBV and Abbott Laboratories ABT to provide the details of how they intend to utilize major savings from the tax overhaul. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Joh... |
25,624 | 2018-03-08 00:00:00 UTC | Want to be a Buy and Hold Investor? 3 Strategies | ABBV | https://www.nasdaq.com/articles/want-be-buy-and-hold-investor-3-strategies-2018-03-08 | null | null | (0: 30 ) - Buy and Hold Value Investing
(3: 30 ) - Examples of Successful Long Term Retail Investors
(7: 35 ) - Buy and Hold Strategies
(11: 45 ) - Tracey's Top Stock Picks
(17: 45 ) - Episode Roundup: DEO, MYL, SNE, ABBV, WBA
Welcome to Episode #84 of the Value Investor Podcast
Every week, Tracey Ryniec, the editor of... | (0: 30 ) - Buy and Hold Value Investing (3: 30 ) - Examples of Successful Long Term Retail Investors (7: 35 ) - Buy and Hold Strategies (11: 45 ) - Tracey's Top Stock Picks (17: 45 ) - Episode Roundup: DEO, MYL, SNE, ABBV, WBA Welcome to Episode #84 of the Value Investor Podcast Every week, Tracey Ryniec, the editor of... | (0: 30 ) - Buy and Hold Value Investing (3: 30 ) - Examples of Successful Long Term Retail Investors (7: 35 ) - Buy and Hold Strategies (11: 45 ) - Tracey's Top Stock Picks (17: 45 ) - Episode Roundup: DEO, MYL, SNE, ABBV, WBA Welcome to Episode #84 of the Value Investor Podcast Every week, Tracey Ryniec, the editor of... | (0: 30 ) - Buy and Hold Value Investing (3: 30 ) - Examples of Successful Long Term Retail Investors (7: 35 ) - Buy and Hold Strategies (11: 45 ) - Tracey's Top Stock Picks (17: 45 ) - Episode Roundup: DEO, MYL, SNE, ABBV, WBA Welcome to Episode #84 of the Value Investor Podcast Every week, Tracey Ryniec, the editor of... | (0: 30 ) - Buy and Hold Value Investing (3: 30 ) - Examples of Successful Long Term Retail Investors (7: 35 ) - Buy and Hold Strategies (11: 45 ) - Tracey's Top Stock Picks (17: 45 ) - Episode Roundup: DEO, MYL, SNE, ABBV, WBA Welcome to Episode #84 of the Value Investor Podcast Every week, Tracey Ryniec, the editor of... |
25,625 | 2018-03-08 00:00:00 UTC | Want to be a Buy and Hold Investor? 3 Strategies | ABBV | https://www.nasdaq.com/articles/want-be-buy-and-hold-investor-3-strategies-2018-03-08-0 | null | null | Welcome to Episode #84 of the Value Investor Podcast
Every week, Tracey Ryniec, the editor of Zacks Value Investor portfolio service , shares some of her top value investing tips and stock picks.
Do you want to be a buy and hold investor but just don't know where to start?
Buy and hold investing is one of the toughest ... | AbbVie ABBV is a rare growth and value stock. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Sony Corp Ord (SNE): Free Stock Analysis Report Diageo PLC (DEO): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis R... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Sony Corp Ord (SNE): Free Stock Analysis Report Diageo PLC (DEO): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis Report To read this article on Zacks.com click ... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Sony Corp Ord (SNE): Free Stock Analysis Report Diageo PLC (DEO): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis Report To read this article on Zacks.com click ... | AbbVie ABBV is a rare growth and value stock. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Sony Corp Ord (SNE): Free Stock Analysis Report Diageo PLC (DEO): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis R... |
25,626 | 2018-03-08 00:00:00 UTC | Biotech Stock Round Up: Regeneron Submits sBLA, Biogen to Withdraw Zinbryta | ABBV | https://www.nasdaq.com/articles/biotech-stock-round-up%3A-regeneron-submits-sbla-biogen-to-withdraw-zinbryta-2018-03-08 | null | null | Key highlights of the week include FDA's acceptance of Regeneron/Sanofi's Dupixent sBLA for asthma, Biogen/AbbVie's decision to withdraw multiple sclerosis drug, Zinbryta, due to risk of liver failure and Celgene's completion of Juno acquisition.
Recap of the Week's Most Important Stories
Regeneron/Sanofi's Dupixent sB... | Key highlights of the week include FDA's acceptance of Regeneron/Sanofi's Dupixent sBLA for asthma, Biogen/AbbVie's decision to withdraw multiple sclerosis drug, Zinbryta, due to risk of liver failure and Celgene's completion of Juno acquisition. Biogen/AbbVie To Withdraw Zinbryta : Biogen BIIB and partner AbbVie ABBV ... | Key highlights of the week include FDA's acceptance of Regeneron/Sanofi's Dupixent sBLA for asthma, Biogen/AbbVie's decision to withdraw multiple sclerosis drug, Zinbryta, due to risk of liver failure and Celgene's completion of Juno acquisition. Click to get this free report Sanofi (SNY): Free Stock Analysis Report Ab... | Click to get this free report Sanofi (SNY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Biogen Inc. (BIIB): Fre... | Key highlights of the week include FDA's acceptance of Regeneron/Sanofi's Dupixent sBLA for asthma, Biogen/AbbVie's decision to withdraw multiple sclerosis drug, Zinbryta, due to risk of liver failure and Celgene's completion of Juno acquisition. Biogen/AbbVie To Withdraw Zinbryta : Biogen BIIB and partner AbbVie ABBV ... |
25,627 | 2018-03-06 00:00:00 UTC | Profit From Share Buyback Boom With These ETFs | ABBV | https://www.nasdaq.com/articles/profit-share-buyback-boom-these-etfs-2018-03-06 | null | null | President Donald Trump's biggest tax overhaul in decades has raised the appeal of buyback ETFs. This is especially true as a massive $1.4-trillion tax cut and the repatriation policy have prompted companies from almost every sector to boost their multi-billion dollar share buyback program this year.
Notably, approximat... | This was followed by $22.6 billion for Wells Fargo WFC , $15 billion for Pepsico PEP , $10 billion for Abbvie ABBV and $10 billion for Amgen AMGN . Click to get this free report Cisco Systems, Inc. (CSCO): Free Stock Analysis Report JPMorgan Chase & Co. (JPM): Free Stock Analysis Report Wells Fargo & Company (WFC): Fre... | This was followed by $22.6 billion for Wells Fargo WFC , $15 billion for Pepsico PEP , $10 billion for Abbvie ABBV and $10 billion for Amgen AMGN . Click to get this free report Cisco Systems, Inc. (CSCO): Free Stock Analysis Report JPMorgan Chase & Co. (JPM): Free Stock Analysis Report Wells Fargo & Company (WFC): Fre... | Click to get this free report Cisco Systems, Inc. (CSCO): Free Stock Analysis Report JPMorgan Chase & Co. (JPM): Free Stock Analysis Report Wells Fargo & Company (WFC): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Pepsico, Inc. (PEP): Free Stock Analysis Report The Goldman Sachs Group, Inc.... | This was followed by $22.6 billion for Wells Fargo WFC , $15 billion for Pepsico PEP , $10 billion for Abbvie ABBV and $10 billion for Amgen AMGN . Click to get this free report Cisco Systems, Inc. (CSCO): Free Stock Analysis Report JPMorgan Chase & Co. (JPM): Free Stock Analysis Report Wells Fargo & Company (WFC): Fre... |
25,628 | 2018-03-06 00:00:00 UTC | Gilead Announces Positive Data on New HIV Therapy Biktarvy | ABBV | https://www.nasdaq.com/articles/gilead-announces-positive-data-on-new-hiv-therapy-biktarvy-2018-03-06 | null | null | Gilead Sciences, Inc.GILD announced encouraging 48-weeks results from a phase III study (Study 1961) among 470 virologically suppressed adult women with HIV infection at the International Workshop on HIV and Women and at the 2018 Conference on Retroviruses and Opportunistic Infections ("CROI") in Boston (Poster 2539).
... | Gilead is banking on its HIV franchise which has been under tremendous pressure for a while due to lower patient starts and increased competition from AbbVie's ABBV therapies. Click to get this free report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Regeneron Pha... | Click to get this free report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Gilead is banking o... | Click to get this free report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Gilead is banking o... | Gilead is banking on its HIV franchise which has been under tremendous pressure for a while due to lower patient starts and increased competition from AbbVie's ABBV therapies. Click to get this free report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Regeneron Pha... |
25,629 | 2018-03-05 00:00:00 UTC | Here's My Top Stock to Buy in March | ABBV | https://www.nasdaq.com/articles/heres-my-top-stock-buy-march-2018-03-05 | null | null | March is known for quite a few things. There's college basketball's "March madness." Julius Caesar was assassinated on the Ides of March. March flowers, of course, bring April showers. St. Patrick's Day brings out a lot of green clothes. And in much of the U.S., we have the beginning of daylight-saving time, when every... | Including the time that AbbVie was part of Abbott, the company has a track record of 46 consecutive years of dividend increases. Rick Gonzalez, AbbVie's CEO, stated at a major healthcare conference in January that the company believes it will generate $35 billion in risk-adjusted non-Humira sales by 2025. And if you fa... | Including the time that AbbVie was part of Abbott, the company has a track record of 46 consecutive years of dividend increases. In 2017, AbbVie ranked as the top big pharma stock in total shareholder return. AbbVie has what I consider to be a fantastic combination of a high dividend yield, a strong track record of div... | Here's why AbbVie (NYSE: ABBV) is my top stock to buy in March. Dividend AbbVie stock is up more than 80% over the past 12 months and more than 15% so far this year. Some might ask, "Why not wait for AbbVie's share price to come down some and buy on the dip?" | And if you factor in the solid growth prospects for the drugmaker over the next five years, AbbVie stock appears even more attractively valued. Here's why AbbVie (NYSE: ABBV) is my top stock to buy in March. Dividend AbbVie stock is up more than 80% over the past 12 months and more than 15% so far this year. |
25,630 | 2018-03-05 00:00:00 UTC | 10 Companies Making Huge Stock Buybacks in 2018 | ABBV | https://www.nasdaq.com/articles/10-companies-making-huge-stock-buybacks-2018-2018-03-05 | null | null | For almost two years, investors feared that the wave of stock buybacks that helped drive the market to record highs was finally coming to a close. Those quarterly buybacks peaked during the first quarter of 2016, plunged by the third quarter of that year, then simply leveled off at sub-par levels through the third quar... | Abbvie ( ABBV , $115.04) is playing the same card, allocating $10 billion of its own to shrink the number of shares in its float. There is one difference: While Amgen's $10 billion commitment is in addition to its existing repurchase program, AbbVie's new buybacks plan replaces the previous one. That's not the only way... | Abbvie ( ABBV , $115.04) is playing the same card, allocating $10 billion of its own to shrink the number of shares in its float. There is one difference: While Amgen's $10 billion commitment is in addition to its existing repurchase program, AbbVie's new buybacks plan replaces the previous one. That's not the only way... | SEE ALSO: 11 Best Health Care Stocks to Buy Buyback commitment: $15 billion If you were impressed by AbbVie's $10 billion buyback, beverage and snack giant PepsiCo ( PEP , $109.04) has one-upped the pharmaceutical company. Abbvie ( ABBV , $115.04) is playing the same card, allocating $10 billion of its own to shrink th... | Abbvie ( ABBV , $115.04) is playing the same card, allocating $10 billion of its own to shrink the number of shares in its float. There is one difference: While Amgen's $10 billion commitment is in addition to its existing repurchase program, AbbVie's new buybacks plan replaces the previous one. That's not the only way... |
25,631 | 2018-03-04 00:00:00 UTC | 3 Stocks With Blazingly Fast-Growing Dividends | ABBV | https://www.nasdaq.com/articles/3-stocks-blazingly-fast-growing-dividends-2018-03-04 | null | null | Some dividend stocks belong in a league of their own. For these stocks, the dividend yields look great. The companies are in strong financial shape to keep the dividend checks flowing. But even better, their dividend payments are growing incredibly fast.
Not many stocks fit those criteria. But AbbVie (NYSE: ABBV) , Boe... | But AbbVie (NYSE: ABBV) , Boeing (NYSE: BA) , and Texas Instruments (NASDAQ: TXN) do. AbbVie AbbVie increased its dividend by 88% over the last three years. Since being spun off from parent Abbott Labs in 2013, AbbVie's dividend has soared 140%. | While Humira still accounts for 65% of AbbVie's total revenue, the company has other products that will help generate higher cash flow over the next several years. But AbbVie (NYSE: ABBV) , Boeing (NYSE: BA) , and Texas Instruments (NASDAQ: TXN) do. AbbVie AbbVie increased its dividend by 88% over the last three years. | AbbVie AbbVie increased its dividend by 88% over the last three years. Boeing Boeing only narrowly trails AbbVie, with dividend growth over the past three years of just a little below 88%. But AbbVie (NYSE: ABBV) , Boeing (NYSE: BA) , and Texas Instruments (NASDAQ: TXN) do. | AbbVie AbbVie increased its dividend by 88% over the last three years. But AbbVie (NYSE: ABBV) , Boeing (NYSE: BA) , and Texas Instruments (NASDAQ: TXN) do. Since being spun off from parent Abbott Labs in 2013, AbbVie's dividend has soared 140%. |
25,632 | 2018-03-02 00:00:00 UTC | Notable ETF Inflow Detected - MTUM, BA, ABBV, AMAT | ABBV | https://www.nasdaq.com/articles/notable-etf-inflow-detected-mtum-ba-abbv-amat-2018-03-02 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Edge MSCI USA Momentum Factor ETF (Symbol: MTUM) where we have detected an approximate $194.3 million dollar inflow -- that's a 2.6% increase week over week in outstanding units (fr... | Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is off about 3.6%, AbbVie Inc (Symbol: ABBV) is off about 1.3%, and Applied Materials, Inc. (Symbol: AMAT) is lower by about 1.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ET... | Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is off about 3.6%, AbbVie Inc (Symbol: ABBV) is off about 1.3%, and Applied Materials, Inc. (Symbol: AMAT) is lower by about 1.3%. For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one year ... | Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is off about 3.6%, AbbVie Inc (Symbol: ABBV) is off about 1.3%, and Applied Materials, Inc. (Symbol: AMAT) is lower by about 1.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ET... | Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is off about 3.6%, AbbVie Inc (Symbol: ABBV) is off about 1.3%, and Applied Materials, Inc. (Symbol: AMAT) is lower by about 1.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ET... |
25,633 | 2018-03-02 00:00:00 UTC | 3 Top Dividend Stocks to Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-top-dividend-stocks-buy-right-now-2018-03-02 | null | null | What do United Parcel Service (NYSE: UPS) , AbbVie Inc. (NYSE: ABBV) , and Walt Disney Co. (NYSE: DIS) have in common? They're all dividend-friendly companies that Motley Fool investors think should be included in income portfolios. Are these stocks a perfect fit for your portfolio? Here's how these dividend stalwarts ... | What do United Parcel Service (NYSE: UPS) , AbbVie Inc. (NYSE: ABBV) , and Walt Disney Co. (NYSE: DIS) have in common? Todd Campbell (AbbVie): If you like stocks with double-digit growth on their top and bottom lines and are increasing their dividends at an eye-popping rate, then you ought to love AbbVie. The clarity i... | What do United Parcel Service (NYSE: UPS) , AbbVie Inc. (NYSE: ABBV) , and Walt Disney Co. (NYSE: DIS) have in common? Todd Campbell (AbbVie): If you like stocks with double-digit growth on their top and bottom lines and are increasing their dividends at an eye-popping rate, then you ought to love AbbVie. The clarity i... | What do United Parcel Service (NYSE: UPS) , AbbVie Inc. (NYSE: ABBV) , and Walt Disney Co. (NYSE: DIS) have in common? Todd Campbell (AbbVie): If you like stocks with double-digit growth on their top and bottom lines and are increasing their dividends at an eye-popping rate, then you ought to love AbbVie. The clarity i... | What do United Parcel Service (NYSE: UPS) , AbbVie Inc. (NYSE: ABBV) , and Walt Disney Co. (NYSE: DIS) have in common? Todd Campbell (AbbVie): If you like stocks with double-digit growth on their top and bottom lines and are increasing their dividends at an eye-popping rate, then you ought to love AbbVie. The clarity i... |
25,634 | 2018-02-28 00:00:00 UTC | 4 Buy-Ranked Large Cap Pharma Stocks to Boost Your Portfolio | ABBV | https://www.nasdaq.com/articles/4-buy-ranked-large-cap-pharma-stocks-to-boost-your-portfolio-2018-02-28-0 | null | null | After rising 16.3% last year, the Large Cap Pharmaceutical industry has risen 1.9% this year so far. It has however underperformed the 4% gain for the S&P 500 in the same time frame.
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest... | Click to get this free report Sanofi (SNY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report H Lundbeck A/S (HLUYY): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report... | Click to get this free report Sanofi (SNY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report H Lundbeck A/S (HLUYY): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report... | Click to get this free report Sanofi (SNY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report H Lundbeck A/S (HLUYY): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report... | Click to get this free report Sanofi (SNY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report H Lundbeck A/S (HLUYY): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report... |
25,635 | 2018-02-27 00:00:00 UTC | Pfizer Gets Mixed Feedback on Cancer Treatments From CHMP | ABBV | https://www.nasdaq.com/articles/pfizer-gets-mixed-feedback-on-cancer-treatments-from-chmp-2018-02-27 | null | null | Pfizer Inc.PFE announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended that two of its hematology medicines be granted marketing authorizations in the EU. However, the committee gave a negative opinion, recommending against label expansion of Pfize... | Other large-cap pharma stocks worth considering are H. Lundbeck HLUYY , AbbVie ABBV and Novo Nordisk NVO . While H. Lundbeck sports a Zacks Rank #1 (Strong Buy), AbbVie and Novo Nordisk have the same Zacks Rank as Pfizer. AbbVie's shares are up 25.6% this year so far. | While H. Lundbeck sports a Zacks Rank #1 (Strong Buy), AbbVie and Novo Nordisk have the same Zacks Rank as Pfizer. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report H Lundbeck A/S (HLUYY): Free St... | While H. Lundbeck sports a Zacks Rank #1 (Strong Buy), AbbVie and Novo Nordisk have the same Zacks Rank as Pfizer. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report H Lundbeck A/S (HLUYY): Free St... | While H. Lundbeck sports a Zacks Rank #1 (Strong Buy), AbbVie and Novo Nordisk have the same Zacks Rank as Pfizer. Other large-cap pharma stocks worth considering are H. Lundbeck HLUYY , AbbVie ABBV and Novo Nordisk NVO . AbbVie's shares are up 25.6% this year so far. |
25,636 | 2018-02-27 00:00:00 UTC | 3 Reasons AbbVie Inc. Stock Could Keep Soaring in 2018 | ABBV | https://www.nasdaq.com/articles/3-reasons-abbvie-inc-stock-could-keep-soaring-2018-2018-02-27 | null | null | We might be in the middle of the first quarter, but AbbVie Inc. (NYSE: ABBV) has already delivered enough good news for a whole year. It's been getting hard to pick a favorite indicator, but raising earnings expectations for the year 14% higher was a big one. With operations firing on all cylinders, it's no wonder the ... | At 65% of total revenue, replacing its eventual losses to biosimilar competition is a top priority Last summer, AbbVie reported results from a pivotal trial with upadacitinib and patients that didn't respond to previous treatment with three separate types of conventional therapies available today. By eventually expandi... | Risankizumab: Potential psoriasis blockbuster Upadacitinib isn't the only anti-inflammatory candidate with blockbuster potential in AbbVie's late-stage pipeline. During a pivotal study, 68.5% of patients treated with AbbVie's Elagolix achieved a clinical response, versus just 8.7% in the placebo group. We might be in t... | At 65% of total revenue, replacing its eventual losses to biosimilar competition is a top priority Last summer, AbbVie reported results from a pivotal trial with upadacitinib and patients that didn't respond to previous treatment with three separate types of conventional therapies available today. By eventually expandi... | AbbVie thinks its late-stage candidate upadacitinib could be the most popular member of a new class of drugs aiming to treat these diseases. We might be in the middle of the first quarter, but AbbVie Inc. (NYSE: ABBV) has already delivered enough good news for a whole year. At 65% of total revenue, replacing its eventu... |
25,637 | 2018-02-27 00:00:00 UTC | ABBV Crosses Above Average Analyst Target | ABBV | https://www.nasdaq.com/articles/abbv-crosses-above-average-analyst-target-2018-02-27 | null | null | In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $119.92, changing hands for $121.54/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a... | In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $119.92, changing hands for $121.54/share. But the whole reason to look at the average ABBV price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contribution... | In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $119.92, changing hands for $121.54/share. But the whole reason to look at the average ABBV price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contribution... | There are 13 different analyst targets contributing to that average for AbbVie Inc, but the average is just that - a mathematical average. And so with ABBV crossing above that average target price of $119.92/share, investors in ABBV have been given a good signal to spend fresh time assessing the company and deciding fo... | There are 13 different analyst targets contributing to that average for AbbVie Inc, but the average is just that - a mathematical average. In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $119.92, changing hands for $121.54/share. But the whole reaso... |
25,638 | 2018-02-27 00:00:00 UTC | 3 Top Pharma Stocks With Dividend Yields Over 3% | ABBV | https://www.nasdaq.com/articles/3-top-pharma-stocks-dividend-yields-over-3-2018-02-27 | null | null | It's no secret that investing in dividend-paying stocks is one of the best ways for everyday investors to create an income stream large enough to make their retirement dreams a reality. Merck & Co., Inc. (NYSE: MRK) , Pfizer Inc. (NYSE: PFE) , and AbbVie Inc. (NYSE: ABBV) all offer yields of 3.2% or higher right now. W... | AbbVie intends to submit a rheumatoid arthritis application to regulators in the second half of the year, and pivotal trials with Crohn's disease and eczema patients are underway. Merck & Co., Inc. (NYSE: MRK) , Pfizer Inc. (NYSE: PFE) , and AbbVie Inc. (NYSE: ABBV) all offer yields of 3.2% or higher right now. That's ... | Merck & Co., Inc. (NYSE: MRK) , Pfizer Inc. (NYSE: PFE) , and AbbVie Inc. (NYSE: ABBV) all offer yields of 3.2% or higher right now. That's not terrible, but you can probably do better with Pfizer or AbbVie. AbbVie Inc.: What patent cliff? | Although that's a bit less than those of Pfizer and Merck, AbbVie grew adjusted earnings 16.2% to $5.60 last year and expects its bottom line to grow another 32% in 2018. Merck & Co., Inc. (NYSE: MRK) , Pfizer Inc. (NYSE: PFE) , and AbbVie Inc. (NYSE: ABBV) all offer yields of 3.2% or higher right now. That's not terri... | Merck & Co., Inc. (NYSE: MRK) , Pfizer Inc. (NYSE: PFE) , and AbbVie Inc. (NYSE: ABBV) all offer yields of 3.2% or higher right now. That's not terrible, but you can probably do better with Pfizer or AbbVie. AbbVie Inc.: What patent cliff? |
25,639 | 2018-02-26 00:00:00 UTC | Gilead Sciences: The Oncology Company? | ABBV | https://www.nasdaq.com/articles/gilead-sciences-oncology-company-2018-02-26 | null | null | Gilead Sciences (NASDAQ: GILD) , the company known for its revolutionary infectious-diseases treatments such as Viread for HIV and Harvoni for hepatitis C, is in the midst of a bold pivot to cell-based cancer treatments as one of its core value drivers.
The reason? New competitive threats from AbbVie 's (NYSE: ABBV) Ma... | New competitive threats from AbbVie 's (NYSE: ABBV) Mavyret in hep C, and GlaxoSmithKline 's (NYSE: GSK) Tivicay and Epivir in HIV, are currently challenging the biotech's dominance in these two key markets. The long and short of it is that Gilead's hep C revenues have been shrinking at a staggering rate, thanks, in la... | New competitive threats from AbbVie 's (NYSE: ABBV) Mavyret in hep C, and GlaxoSmithKline 's (NYSE: GSK) Tivicay and Epivir in HIV, are currently challenging the biotech's dominance in these two key markets. The long and short of it is that Gilead's hep C revenues have been shrinking at a staggering rate, thanks, in la... | New competitive threats from AbbVie 's (NYSE: ABBV) Mavyret in hep C, and GlaxoSmithKline 's (NYSE: GSK) Tivicay and Epivir in HIV, are currently challenging the biotech's dominance in these two key markets. The long and short of it is that Gilead's hep C revenues have been shrinking at a staggering rate, thanks, in la... | New competitive threats from AbbVie 's (NYSE: ABBV) Mavyret in hep C, and GlaxoSmithKline 's (NYSE: GSK) Tivicay and Epivir in HIV, are currently challenging the biotech's dominance in these two key markets. The long and short of it is that Gilead's hep C revenues have been shrinking at a staggering rate, thanks, in la... |
25,640 | 2018-02-26 00:00:00 UTC | AbbVie (ABBV) Up 9.7% Since Earnings Report: Can It Continue? | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-up-9.7-since-earnings-report%3A-can-it-continue-2018-02-26 | null | null | A month has gone by since the last earnings report for AbbVie Inc.ABBV . Shares have added about 9.7% in that time frame, outperforming the market.
Will the recent positive trend continue leading up to its next earnings release, or is ABBV due for a pullback? Before we dive into how investors and analysts have reacted ... | A month has gone by since the last earnings report for AbbVie Inc.ABBV . Will the recent positive trend continue leading up to its next earnings release, or is ABBV due for a pullback? AbbVie Tops Q4 Earnings & Revenues, Ups 2018 Guidance AbbVie reported better-than-expected results for the fourth quarter of 2017. | AbbVie Inc. Price and Consensus AbbVie Inc. Price and Consensus | AbbVie Inc. Quote VGM Scores At this time, ABBV has an average Growth Score of C, while it is doing a lot better on the momentum front with A. A month has gone by since the last earnings report for AbbVie Inc.ABBV . Will the recent positive trend continu... | In 2017, AbbVie met its expectations of recording Imbruvica global revenues of more than $2.4 billion with sales in the United States crossing $2 billion. A month has gone by since the last earnings report for AbbVie Inc.ABBV . Will the recent positive trend continue leading up to its next earnings release, or is ABBV ... | A month has gone by since the last earnings report for AbbVie Inc.ABBV . Will the recent positive trend continue leading up to its next earnings release, or is ABBV due for a pullback? AbbVie Tops Q4 Earnings & Revenues, Ups 2018 Guidance AbbVie reported better-than-expected results for the fourth quarter of 2017. |
25,641 | 2018-02-23 00:00:00 UTC | New Strong Buy Stocks for February 23rd | ABBV | https://www.nasdaq.com/articles/new-strong-buy-stocks-february-23rd-2018-02-23 | null | null | Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Air Transport Services Group, Inc. (ATSG): This company that provides aircraft leasing, airline operations, and aircraft maintenance and other support services has seen the Zacks Consensus Estimate for its current year earnings increasing 1.2% over t... | HollyFrontier Corporation Price and Consensus HollyFrontier Corporation price-consensus-chart | HollyFrontier Corporation Quote AbbVie Inc. (ABBV): This manufacturer of pharmaceutical products has seen the Zacks Consensus Estimate for its current year earnings increasing 14.2% over the last 60 days. AbbVie Inc. Price a... | HollyFrontier Corporation Price and Consensus HollyFrontier Corporation price-consensus-chart | HollyFrontier Corporation Quote AbbVie Inc. (ABBV): This manufacturer of pharmaceutical products has seen the Zacks Consensus Estimate for its current year earnings increasing 14.2% over the last 60 days. Click to get this f... | Click to get this free report HollyFrontier Corporation (HFC): Free Stock Analysis Report Best Buy Co., Inc. (BBY): Free Stock Analysis Report Air Transport Services Group, Inc (ATSG): Free Stock Analysis Report ArcBest Corporation (ARCB): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To rea... | AbbVie Inc. Price and Consensus AbbVie Inc. price-consensus-chart | AbbVie Inc. Quote You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here Zacks Top 10 Stocks for 2018 In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety o... |
25,642 | 2018-02-23 00:00:00 UTC | Pharma Stock Roundup: AZN's Imfinzi Gets 2nd FDA Nod, MRK to Buy Australian Firm | ABBV | https://www.nasdaq.com/articles/pharma-stock-roundup%3A-azns-imfinzi-gets-2nd-fda-nod-mrk-to-buy-australian-firm-2018-02-23 | null | null | Key announcements this week included the FDA approval for a second indication of AstraZeneca's AZN Imfinzi and an acquisition offer by Merck MRK . AbbVie ABBV presented new data on two pipeline candidates and announced an Alzheimer's deal with a small biotech.
Recap of the Week's Most Important Stories
AstraZeneca's Im... | AbbVie ABBV presented new data on two pipeline candidates and announced an Alzheimer's deal with a small biotech. (Read more: Merck to Buy Australian Firm to Boost Immunotherapy Pipeline ) AbbVie Reports New Mid-Stage Data on Upadacitinib: AbbVie announced new data from the phase II CELEST study, which evaluated multip... | (Read more: Merck to Buy Australian Firm to Boost Immunotherapy Pipeline ) AbbVie Reports New Mid-Stage Data on Upadacitinib: AbbVie announced new data from the phase II CELEST study, which evaluated multiple dosing regimens of its JAK1 inhibitor, upadacitinib for Crohn's disease through week 52. Click to get this free... | (Read more: Merck to Buy Australian Firm to Boost Immunotherapy Pipeline ) AbbVie Reports New Mid-Stage Data on Upadacitinib: AbbVie announced new data from the phase II CELEST study, which evaluated multiple dosing regimens of its JAK1 inhibitor, upadacitinib for Crohn's disease through week 52. Click to get this free... | (Read more: Merck to Buy Australian Firm to Boost Immunotherapy Pipeline ) AbbVie Reports New Mid-Stage Data on Upadacitinib: AbbVie announced new data from the phase II CELEST study, which evaluated multiple dosing regimens of its JAK1 inhibitor, upadacitinib for Crohn's disease through week 52. AbbVie ABBV presented ... |
25,643 | 2018-02-22 00:00:00 UTC | Abbvie's Uterine Fibrosis Candidate Meets Goal in Study | ABBV | https://www.nasdaq.com/articles/abbvies-uterine-fibrosis-candidate-meets-goal-in-study-2018-02-22 | null | null | AbbVie Inc. ( ABBV ) along with partner Neurocrine Biosciences, announced that the phase III study oftheir late stage candidateelagolix met its primary endpoint in women with uterine fibroids. Top-line results from the first of the two pivotal phase III studies on elagolix (ELARIS UF-I) revealed that at six month, elag... | AbbVie Inc. ( ABBV ) along with partner Neurocrine Biosciences, announced that the phase III study oftheir late stage candidateelagolix met its primary endpoint in women with uterine fibroids. So far this year, AbbVie's shares price have returned 92.1%, comparing favorably with 11.1% gain recorded by the industry . In ... | AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank Abbvie currently carries a Zacks Rank #2 (Buy). Click to get this free report Allergan plc (AGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Bayer Aktiengesellschaft (BAYRY): Free Stock Analysis Report Voyager Therapeutics... | AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank Abbvie currently carries a Zacks Rank #2 (Buy). Click to get this free report Allergan plc (AGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Bayer Aktiengesellschaft (BAYRY): Free Stock Analysis Report Voyager Therapeutics... | AbbVie Inc. ( ABBV ) along with partner Neurocrine Biosciences, announced that the phase III study oftheir late stage candidateelagolix met its primary endpoint in women with uterine fibroids. So far this year, AbbVie's shares price have returned 92.1%, comparing favorably with 11.1% gain recorded by the industry . In ... |
25,644 | 2018-02-21 00:00:00 UTC | Can Johnson & Johnson Replace Remicade for $100 Million Upfront? | ABBV | https://www.nasdaq.com/articles/can-johnson-johnson-replace-remicade-100-million-upfront-2018-02-21 | null | null | As huge piles of overseas cash make their way back to big U.S. drugmakers, biotech buyouts dominate the headlines. While most of us were watching the big money, Johnson & Johnson (NYSE: JNJ) inked a tiny little deal with Theravance Biopharma (NASDAQ: TBPH) that could help the world's largest healthcare company solve a ... | Although AbbVie owns rights to a portion of the revenue this popular leukemia drug generates, J&J's portion of Imbruvica sales bounded 51% higher in 2017 to $1.9 billion and could go much further. That's why Remicade has a black box on its drug label that warns of increased risk of deadly opportunistic infections and r... | Although AbbVie owns rights to a portion of the revenue this popular leukemia drug generates, J&J's portion of Imbruvica sales bounded 51% higher in 2017 to $1.9 billion and could go much further. That's why Johnson & Johnson recently handed Theravance Biopharma $100 million upfront for rights to TD-1473, an oral Janus... | Although AbbVie owns rights to a portion of the revenue this popular leukemia drug generates, J&J's portion of Imbruvica sales bounded 51% higher in 2017 to $1.9 billion and could go much further. While most of us were watching the big money, Johnson & Johnson (NYSE: JNJ) inked a tiny little deal with Theravance Biopha... | Although AbbVie owns rights to a portion of the revenue this popular leukemia drug generates, J&J's portion of Imbruvica sales bounded 51% higher in 2017 to $1.9 billion and could go much further. Next steps This year, Theravance Biopharma will begin two mid-stage clinical trials with TD-1473, one for treatment of Croh... |
25,645 | 2018-02-21 00:00:00 UTC | Why TG Therapeutics Stock Jumped 10% Today | ABBV | https://www.nasdaq.com/articles/why-tg-therapeutics-stock-jumped-10-today-2018-02-21 | null | null | What happened
After reporting early-stage trial results for one of the cancer drugs in its pipeline, TG Therapeutics (NASDAQ: TGTX) jumped 9.9% on Wednesday.
So what
The clinical-stage biotech stock has previously provided interesting trial data for TG-1101, or ublituximab, when used with AbbVie 's (NYSE: ABBV) and Joh... | So what The clinical-stage biotech stock has previously provided interesting trial data for TG-1101, or ublituximab, when used with AbbVie 's (NYSE: ABBV) and Johnson & Johnson 's (NYSE: JNJ) Imbruvica in leukemia patients. What happened After reporting early-stage trial results for one of the cancer drugs in its pipel... | So what The clinical-stage biotech stock has previously provided interesting trial data for TG-1101, or ublituximab, when used with AbbVie 's (NYSE: ABBV) and Johnson & Johnson 's (NYSE: JNJ) Imbruvica in leukemia patients. Today, it unveiled positive results from a trial evaluating another drug, umbralisib. Specifical... | So what The clinical-stage biotech stock has previously provided interesting trial data for TG-1101, or ublituximab, when used with AbbVie 's (NYSE: ABBV) and Johnson & Johnson 's (NYSE: JNJ) Imbruvica in leukemia patients. Specifically, umbralisib was clinically active with 85% of relapsed or refractory CLL patients a... | So what The clinical-stage biotech stock has previously provided interesting trial data for TG-1101, or ublituximab, when used with AbbVie 's (NYSE: ABBV) and Johnson & Johnson 's (NYSE: JNJ) Imbruvica in leukemia patients. Now what Ublituximab's overall response rate alongside Imbruvica is 81%, and if adding umbralisi... |
25,646 | 2018-02-20 00:00:00 UTC | Health Care Sector Update for 02/20/2018: AIMT, CELG, LLY, VYGR, ABBV | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-02202018-aimt-celg-lly-vygr-abbv-2018-02-20 | null | null | Top Health-care stocks:
JNJ: flat
PFE: flat
ABT: flat
MRK: +0.2%
AMGN: flat
Health care shares were slightly higher ahead of the bell on Tuesday.
Expected movers:
- Aimmune ( AIMT ): AR101 meets primary endpoint in study of peanut allergy
- Celgene ( CELG ): says Otezla shows potential in reducing oral ulcers in Behcet... | Expected movers: - Aimmune ( AIMT ): AR101 meets primary endpoint in study of peanut allergy - Celgene ( CELG ): says Otezla shows potential in reducing oral ulcers in Behcet's disease patients in phase 3 study - Eli Lilly ( LLY ): phase 3b study of Taltz shows improvement in impact of genital psoriasis on sexual activ... | Expected movers: - Aimmune ( AIMT ): AR101 meets primary endpoint in study of peanut allergy - Celgene ( CELG ): says Otezla shows potential in reducing oral ulcers in Behcet's disease patients in phase 3 study - Eli Lilly ( LLY ): phase 3b study of Taltz shows improvement in impact of genital psoriasis on sexual activ... | Expected movers: - Aimmune ( AIMT ): AR101 meets primary endpoint in study of peanut allergy - Celgene ( CELG ): says Otezla shows potential in reducing oral ulcers in Behcet's disease patients in phase 3 study - Eli Lilly ( LLY ): phase 3b study of Taltz shows improvement in impact of genital psoriasis on sexual activ... | Expected movers: - Aimmune ( AIMT ): AR101 meets primary endpoint in study of peanut allergy - Celgene ( CELG ): says Otezla shows potential in reducing oral ulcers in Behcet's disease patients in phase 3 study - Eli Lilly ( LLY ): phase 3b study of Taltz shows improvement in impact of genital psoriasis on sexual activ... |
25,647 | 2018-02-20 00:00:00 UTC | Health Care Sector Update for 02/20/2018: ANAB,VYGR,ABBV,AIMT,CELG | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-02202018-anabvygrabbvaimtcelg-2018-02-20 | null | null | Top Health Care Stocks
JNJ -1.57%
PFE -0.88%
ABT -1.84%
MRK -2.27%
AMGN -0.66%
Health care stocks extended their Tuesday declines, including a more than 1.3% drop for the NYSE Health Care Index in recent trade. Also today, shares of health care companies in the S&P 500 were down nearly 1.2% as a group while the Nasdaq ... | In other sector news: + Voyager Therapeutics ( VYGR ) rallied Tuesday, jumping over 23% higher to an intra-day high of $24.14 a share, that followed the clinical-stage gene therapy company announcing a new collaboration partnership with large-scale drugmaker AbbVie ( ABBV ) to develop potential treatments for Alzheimer... | In other sector news: + Voyager Therapeutics ( VYGR ) rallied Tuesday, jumping over 23% higher to an intra-day high of $24.14 a share, that followed the clinical-stage gene therapy company announcing a new collaboration partnership with large-scale drugmaker AbbVie ( ABBV ) to develop potential treatments for Alzheimer... | In other sector news: + Voyager Therapeutics ( VYGR ) rallied Tuesday, jumping over 23% higher to an intra-day high of $24.14 a share, that followed the clinical-stage gene therapy company announcing a new collaboration partnership with large-scale drugmaker AbbVie ( ABBV ) to develop potential treatments for Alzheimer... | In other sector news: + Voyager Therapeutics ( VYGR ) rallied Tuesday, jumping over 23% higher to an intra-day high of $24.14 a share, that followed the clinical-stage gene therapy company announcing a new collaboration partnership with large-scale drugmaker AbbVie ( ABBV ) to develop potential treatments for Alzheimer... |
25,648 | 2018-02-20 00:00:00 UTC | 3 More Reasons to Buy AbbVie Stock | ABBV | https://www.nasdaq.com/articles/3-more-reasons-buy-abbvie-stock-2018-02-20 | null | null | It's really easy to identify reasons to buy AbbVie (NYSE: ABBV) stock. Humira ranks as the top-selling drug in the world , and sales are still growing. In addition, AbbVie claims one of the hottest cancer drugs on the market with Imbruvica. The company's newest hepatitis C drug, Mavyret, appears to be headed for blockb... | The company's newest hepatitis C drug, Mavyret, appears to be headed for blockbuster sales, and AbbVie generated the best total shareholder return of any big pharma stock over the last three years. More stock buybacks Along with the news of a dividend increase, AbbVie announced that its board of directors has authorize... | The company's newest hepatitis C drug, Mavyret, appears to be headed for blockbuster sales, and AbbVie generated the best total shareholder return of any big pharma stock over the last three years. On Feb. 16, AbbVie announced new results from a phase 2 study of upadacitinib in treating Crohn's disease. It's really eas... | More stock buybacks Along with the news of a dividend increase, AbbVie announced that its board of directors has authorized a new $10 billion stock-repurchase program. So is there any reason not to buy AbbVie stock? 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it ... | But if you need additional reasons to buy the stock, AbbVie provided three more last week. * David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! It's really easy to identify reasons to buy AbbVie (NYSE: ABBV) stock. |
25,649 | 2018-02-20 00:00:00 UTC | Health Care Sector Update for 02/20/2018: VYGR,ABBV,AIMT,CELG | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-02202018-vygrabbvaimtcelg-2018-02-20 | null | null | Top Health Care Stocks
JNJ -1.31%
PFE -0.12%
ABT -1.26%
MRK -2.24%
AMGN +0.16%
Health care stocks were falling Tuesday, including a more than 0.5% decline for the NYSE Health Care Index in recent trading. Shares of health care companies in the S&P 500 were down more than 0.2% as a group while the Nasdaq Biotechnology i... | Among health care stocks moving on news: + Voyager Therapeutics ( VYGR ) rallied Tuesday, jumping over 23% higher to an intra-day high of $24.14 a share, that followed the clinical-stage gene therapy company announcing a new collaboration partnership with large-scale drugmaker AbbVie ( ABBV ) to develop potential treat... | Among health care stocks moving on news: + Voyager Therapeutics ( VYGR ) rallied Tuesday, jumping over 23% higher to an intra-day high of $24.14 a share, that followed the clinical-stage gene therapy company announcing a new collaboration partnership with large-scale drugmaker AbbVie ( ABBV ) to develop potential treat... | Among health care stocks moving on news: + Voyager Therapeutics ( VYGR ) rallied Tuesday, jumping over 23% higher to an intra-day high of $24.14 a share, that followed the clinical-stage gene therapy company announcing a new collaboration partnership with large-scale drugmaker AbbVie ( ABBV ) to develop potential treat... | Among health care stocks moving on news: + Voyager Therapeutics ( VYGR ) rallied Tuesday, jumping over 23% higher to an intra-day high of $24.14 a share, that followed the clinical-stage gene therapy company announcing a new collaboration partnership with large-scale drugmaker AbbVie ( ABBV ) to develop potential treat... |
25,650 | 2018-02-20 00:00:00 UTC | Novartis Psoriasis Drug Cosentyx Positive in SCALP Study | ABBV | https://www.nasdaq.com/articles/novartis-psoriasis-drug-cosentyx-positive-in-scalp-study-2018-02-20 | null | null | Novartis AGNVS ended 2017 on a positive note, courtesy of strong performance of psoriasis drug, Cosentyx.
Cosentyx achieved multi-blockbuster drug status in 2017 on the back of strong growth in three approved indications - psoriasis, ankylosing spondylitis and psoriatic arthritis. The drug has grabbed market share from... | The drug has grabbed market share from rivals - AbbVie's ABBV Humira and Amgen's AMGN Enbrel. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report To read... | Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report To read this article on Zacks.com click here. The drug has grabbed market share from rivals - AbbVie'... | Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report To read this article on Zacks.com click here. The drug has grabbed market share from rivals - AbbVie'... | The drug has grabbed market share from rivals - AbbVie's ABBV Humira and Amgen's AMGN Enbrel. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report To read... |
25,651 | 2018-02-20 00:00:00 UTC | Why Noble Energy, Voyager Therapeutics, and NXP Semiconductors Jumped Today | ABBV | https://www.nasdaq.com/articles/why-noble-energy-voyager-therapeutics-and-nxp-semiconductors-jumped-today-2018-02-20 | null | null | Tuesday saw the broader market turn lower late in the session on weakness in the Dow Jones Industrials . Bad news at the top of the brick-and-mortar retail sector hurt consumer goods stocks, and more generally, investors seemed uncertain whether major benchmarks were ready to return to all-time highs or would have to s... | Voyager partners up Voyager Therapeutics stock soared 22% in the wake of the company's announcement of a collaboration with industry giant AbbVie (NYSE: ABBV) in the fight against Alzheimer's and similar diseases. Under the strategic deal, AbbVie will pay Voyager an up-front payment of $69 million, with the potential t... | Under the strategic deal, AbbVie will pay Voyager an up-front payment of $69 million, with the potential to pay as much as $155 million in preclinical and phase 1 option payments. Voyager partners up Voyager Therapeutics stock soared 22% in the wake of the company's announcement of a collaboration with industry giant A... | Voyager partners up Voyager Therapeutics stock soared 22% in the wake of the company's announcement of a collaboration with industry giant AbbVie (NYSE: ABBV) in the fight against Alzheimer's and similar diseases. Under the strategic deal, AbbVie will pay Voyager an up-front payment of $69 million, with the potential t... | Under the strategic deal, AbbVie will pay Voyager an up-front payment of $69 million, with the potential to pay as much as $155 million in preclinical and phase 1 option payments. Voyager partners up Voyager Therapeutics stock soared 22% in the wake of the company's announcement of a collaboration with industry giant A... |
25,652 | 2018-02-19 00:00:00 UTC | Is AbbVie or Gilead Sciences Stock a Better Buy? | ABBV | https://www.nasdaq.com/articles/abbvie-or-gilead-sciences-stock-better-buy-2018-02-19 | null | null | AbbVie Inc. (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) are two of the world's biggest biotech stocks. However, their sales have been heading in different directions and each has offered up very different forecasts for 2018. Given that these titans are competing head to head for a share in the multibillion-dollar m... | AbbVie Inc. (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) are two of the world's biggest biotech stocks. By that measure, AbbVie is undeniably the better of the two stocks. Because of increased competition from AbbVie and other hepatitis C drugmakers, Gilead Sciences' sales and earnings have been declining since 2016... | Given AbbVie's double-digit top- and bottom-line growth, a recent 35% increase to its quarterly dividend payment, multiple potential blockbuster approvals, and a forward dividend yield of 3.3% that's better than Gilead Sciences' 2.8% rate, AbbVie looks better here, too. AbbVie trades at a forward P/E of 13 and a price-... | Given AbbVie's double-digit top- and bottom-line growth, a recent 35% increase to its quarterly dividend payment, multiple potential blockbuster approvals, and a forward dividend yield of 3.3% that's better than Gilead Sciences' 2.8% rate, AbbVie looks better here, too. Gilead Sciences is forecasting sales of between o... | Gilead Sciences is forecasting sales of between only $20 billion and $21 billion this year, down from $25.7 billion in 2016, and if its sales and profit fall faster than feared, then its valuation advantage could fade, especially if AbbVie over-delivers on its outlook for 13% sales growth this year. AbbVie Inc. (NYSE: ... |
25,653 | 2018-02-19 00:00:00 UTC | AbbVie Presents New Data on Upadacitinib for Crohn's Disease | ABBV | https://www.nasdaq.com/articles/abbvie-presents-new-data-on-upadacitinib-for-crohns-disease-2018-02-19 | null | null | AbbVie Inc.ABBV announced new data from the phase II study on investigational JAK1 inhibitor, upadacitinib. The 52-week CELEST study evaluated upadacitinib in multiple dosing regimens through week 52 in adult patients with Crohn's disease and who were intolerant or had inadequate response to an immunomodulator or tumor... | AbbVie Inc.ABBV announced new data from the phase II study on investigational JAK1 inhibitor, upadacitinib. AbbVie's shares have rallied 92% over a year, outperforming the industry 's growth of 13%. AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank & Other Stocks to Consider AbbVie carries a Zacks Rank... | AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank & Other Stocks to Consider AbbVie carries a Zacks Rank #2 (Buy). Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report XOMA Corporation (XOMA): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report Enanta Ph... | AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank & Other Stocks to Consider AbbVie carries a Zacks Rank #2 (Buy). Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report XOMA Corporation (XOMA): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report Enanta Ph... | AbbVie Inc.ABBV announced new data from the phase II study on investigational JAK1 inhibitor, upadacitinib. AbbVie's shares have rallied 92% over a year, outperforming the industry 's growth of 13%. AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank & Other Stocks to Consider AbbVie carries a Zacks Rank... |
25,654 | 2018-02-19 00:00:00 UTC | 6 Notable Dividend Stocks Boost Payouts, Including Coca-Cola (KO) | ABBV | https://www.nasdaq.com/articles/6-notable-dividend-stocks-boost-payouts-including-coca-cola-ko-2018-02-19 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
The S&P 500 Index bounced back strongly last week, fueled by a continued stretch of positive corporate earnings reports. A handful of dividend stocks added to the bullish sentiment by announcing dividend raises.
Six notable dividend stocks increased their p... | KO Dividend Yield: 3.44% AbbVie Inc (NYSE: ABBV ) moved its quarterly dividend higher by a whopping 35%, increasing it from 71 cents per share to 96 cents. Because of this, ABBV shares trade ex-dividend on April 12. ABBV Dividend Yield: 3.24% 5 Cheap Dividend Stocks With Growing Payouts Medical Properties Trust, Inc. (... | ABBV Dividend Yield: 3.24% 5 Cheap Dividend Stocks With Growing Payouts Medical Properties Trust, Inc. (NYSE: MPW ) increased its quarterly dividend by 4%, raising its payment to 25 cents per share from 24 cents. KO Dividend Yield: 3.44% AbbVie Inc (NYSE: ABBV ) moved its quarterly dividend higher by a whopping 35%, in... | ABBV Dividend Yield: 3.24% 5 Cheap Dividend Stocks With Growing Payouts Medical Properties Trust, Inc. (NYSE: MPW ) increased its quarterly dividend by 4%, raising its payment to 25 cents per share from 24 cents. KO Dividend Yield: 3.44% AbbVie Inc (NYSE: ABBV ) moved its quarterly dividend higher by a whopping 35%, in... | KO Dividend Yield: 3.44% AbbVie Inc (NYSE: ABBV ) moved its quarterly dividend higher by a whopping 35%, increasing it from 71 cents per share to 96 cents. Because of this, ABBV shares trade ex-dividend on April 12. ABBV Dividend Yield: 3.24% 5 Cheap Dividend Stocks With Growing Payouts Medical Properties Trust, Inc. (... |
25,655 | 2018-02-17 00:00:00 UTC | This Stock Gets a Gold Medal for Being the Best Blue Chip Biotech | ABBV | https://www.nasdaq.com/articles/stock-gets-gold-medal-being-best-blue-chip-biotech-2018-02-17 | null | null | With worry over its top-selling Humira fading and clarity into plans supporting its future growth, AbbVie Inc. (NYSE: ABBV) is racking up medal-winning returns for investors.
In this clip from The Motley Fool's Industry Focus: Healthcare , analyst Kristine Harjes and contributor Todd Campbell explain how AbbVie's effor... | With worry over its top-selling Humira fading and clarity into plans supporting its future growth, AbbVie Inc. (NYSE: ABBV) is racking up medal-winning returns for investors. In this clip from The Motley Fool's Industry Focus: Healthcare , analyst Kristine Harjes and contributor Todd Campbell explain how AbbVie's effor... | For my third pick, I'm giving the best blue-chip biotech gold medal to AbbVie. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. With worry over its top-selling Humira fading and clarity into plans supporting its future growth, AbbVie I... | In this clip from The Motley Fool's Industry Focus: Healthcare , analyst Kristine Harjes and contributor Todd Campbell explain how AbbVie's efforts to overcome future headwinds due to Humira competition and increase its sales and profit deserve a gold medal. 10 stocks we like better than AbbVie When investing geniuses ... | In this clip from The Motley Fool's Industry Focus: Healthcare , analyst Kristine Harjes and contributor Todd Campbell explain how AbbVie's efforts to overcome future headwinds due to Humira competition and increase its sales and profit deserve a gold medal. With worry over its top-selling Humira fading and clarity int... |
25,656 | 2018-02-16 00:00:00 UTC | AbbVie Hikes Dividend by 35%, Launches $10B Buyback Plan | ABBV | https://www.nasdaq.com/articles/abbvie-hikes-dividend-by-35-launches-%2410b-buyback-plan-2018-02-16 | null | null | AbbVieABBV announced a 35% hike in its quarterly dividend along with the authorization of a new $10 billion share buyback program by the board. AbbVie stock rose more than 1% on Thursday in response to the news.
The dividend was increased from 71 cents per share to 96 cents per share. The cash dividend is payable on Ma... | Moreover, the agreement gave AbbVie ample time to focus on developing its pipeline and launching new products that will help make up for the loss of revenues once biosimilar Humira enters the market. AbbVieABBV announced a 35% hike in its quarterly dividend along with the authorization of a new $10 billion share buybac... | In October last year, AbbVie announced an 11% hike in quarterly dividend to 71 cents per share from 64 cents per share. AbbVie met primary endpoints in several pivotal studies - the key phase III MURANO study of Venclexta plus Roche's RHHBY Rituxan in relapse/refractory chronic lymphocytic leukemia; three phase III stu... | In October last year, AbbVie announced an 11% hike in quarterly dividend to 71 cents per share from 64 cents per share. AbbVie met primary endpoints in several pivotal studies - the key phase III MURANO study of Venclexta plus Roche's RHHBY Rituxan in relapse/refractory chronic lymphocytic leukemia; three phase III stu... | In fact, since its inception in 2013, AbbVie has hiked its dividend by 140%. AbbVieABBV announced a 35% hike in its quarterly dividend along with the authorization of a new $10 billion share buyback program by the board. AbbVie stock rose more than 1% on Thursday in response to the news. |
25,657 | 2018-02-16 00:00:00 UTC | Health Care Sector Update for 02/16/2018: ABBV,APRI,UTHR,PCRX | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-02162018-abbvapriuthrpcrx-2018-02-16 | null | null | Top Health Care Stocks
JNJ +1.73%
PFE +1.93%
ABT +1.47%
MRK +0.76%
AMGN +0.11%
Health care stocks resisted the late weakness affecting most other industry sectors this afternoon, including the NYSE Health Care Index hanging on for 1.1% gain. Also today, shares of health care companies in the S&P 500 were up nearly 1.0%... | Among health care stocks moving on news: AbbVie ( ABBV ) gained Friday, rising almost 4% to a session high of $119.09 a share, after the drug-maker said its Upadacitinib drug candidate continued to show a response after 36 weeks in patients during Phase II testing in patients with Crohn's disease. In other sector news:... | Among health care stocks moving on news: AbbVie ( ABBV ) gained Friday, rising almost 4% to a session high of $119.09 a share, after the drug-maker said its Upadacitinib drug candidate continued to show a response after 36 weeks in patients during Phase II testing in patients with Crohn's disease. The views and opinion... | Among health care stocks moving on news: AbbVie ( ABBV ) gained Friday, rising almost 4% to a session high of $119.09 a share, after the drug-maker said its Upadacitinib drug candidate continued to show a response after 36 weeks in patients during Phase II testing in patients with Crohn's disease. Health care stocks re... | Among health care stocks moving on news: AbbVie ( ABBV ) gained Friday, rising almost 4% to a session high of $119.09 a share, after the drug-maker said its Upadacitinib drug candidate continued to show a response after 36 weeks in patients during Phase II testing in patients with Crohn's disease. Top Health Care Stock... |
25,658 | 2018-02-16 00:00:00 UTC | Stocks To Watch: Bristol-Myers Squibb Sees RS Rating Jump To 83 | ABBV | https://www.nasdaq.com/articles/stocks-watch-bristol-myers-squibb-sees-rs-rating-jump-83-2018-02-16 | null | null | When building your watch list, look for stocks with an 80 or higher RS Rating . Bristol-Myers Squibb ( BMY ) just met that criteria with a new score of 83.
[ibd-display-video id=3105496 width=50 float=left autostart=true] IBD's proprietary RS Rating measures market leadership by showing how a stock's price movement ove... | AbbVie ( ABBV ), Zoetis ( ZTS ) and Novo Nordisk ( NVO ) are among the top 5 highly rated stocks within the group. See How IBD Helps You Make More Money In Stocks Bristol-Myers Squibb has moved more than 5% past a 66.20 entry in a first-stage flat base , meaning it's now out of a proper buy zone. Look for the stock to ... | AbbVie ( ABBV ), Zoetis ( ZTS ) and Novo Nordisk ( NVO ) are among the top 5 highly rated stocks within the group. Biotech And Pharmaceutical Industry And Stock News IBD Stock Rating Upgrades: Rising Relative Strength Why Should You Use IBD's Relative Strength Rating? How Relative Strength Line Can Help You Judge A Sto... | AbbVie ( ABBV ), Zoetis ( ZTS ) and Novo Nordisk ( NVO ) are among the top 5 highly rated stocks within the group. [ibd-display-video id=3105496 width=50 float=left autostart=true] IBD's proprietary RS Rating measures market leadership by showing how a stock's price movement over the last 52 weeks compares to that of t... | AbbVie ( ABBV ), Zoetis ( ZTS ) and Novo Nordisk ( NVO ) are among the top 5 highly rated stocks within the group. [ibd-display-video id=3105496 width=50 float=left autostart=true] IBD's proprietary RS Rating measures market leadership by showing how a stock's price movement over the last 52 weeks compares to that of t... |
25,659 | 2018-02-16 00:00:00 UTC | Top-Rated Stocks: Zoetis Sees Composite Rating Climb To 97 | ABBV | https://www.nasdaq.com/articles/top-rated-stocks-zoetis-sees-composite-rating-climb-97-2018-02-16 | null | null | On Friday, Zoetis ( ZTS ) got an upgrade for its IBD SmartSelect Composite Rating from 91 to 97.
[ibd-display-video id=2385970 width=50 float=left autostart=true] The revised score means the stock currently tops 97% of all other stocks in terms of key performance metrics and technical strength. Winning stocks often hav... | AbbVie ( ABBV ) is the No. On Friday, Zoetis ( ZTS ) got an upgrade for its IBD SmartSelect Composite Rating from 91 to 97. Winning stocks often have a 95 or higher grade in the early stages of a new price run. | AbbVie ( ABBV ) is the No. See How IBD Helps You Make More Money In Stocks The stock earns a 96 EPS Rating, which means its recent quarterly and longer-term annual earnings growth tops 96% of all stocks. In Q4, the company posted 47% earnings growth. | AbbVie ( ABBV ) is the No. [ibd-display-video id=2385970 width=50 float=left autostart=true] The revised score means the stock currently tops 97% of all other stocks in terms of key performance metrics and technical strength. See How IBD Helps You Make More Money In Stocks The stock earns a 96 EPS Rating, which means i... | AbbVie ( ABBV ) is the No. See How IBD Helps You Make More Money In Stocks The stock earns a 96 EPS Rating, which means its recent quarterly and longer-term annual earnings growth tops 96% of all stocks. The company has now posted rising growth in each of the last two reports. |
25,660 | 2018-02-15 00:00:00 UTC | Did AbbVie, Inc. Just Become the Most Shareholder-Friendly Stock in America? | ABBV | https://www.nasdaq.com/articles/did-abbvie-inc-just-become-most-shareholder-friendly-stock-america-2018-02-15 | null | null | AbbVie, Inc. 's (NYSE: ABBV) on a roll and it wants its investors to profit. The company's dividend payments and stock buybacks since becoming public in 2013 have steadily increased, and on Thursday management outlined a new plan to return even more money to its shareholders.
Cashing in on clarity
AbbVie generates 65% ... | Given the additional clarity into Humira's future, a stable of fast-growing drugs, and multiple blockbusters making their way to market, AbbVie should have plenty of cash flow coming in to support dividend payments and buybacks. With a runway toward ongoing double-digit top- and bottom-line growth and a forward dividen... | Given the additional clarity into Humira's future, a stable of fast-growing drugs, and multiple blockbusters making their way to market, AbbVie should have plenty of cash flow coming in to support dividend payments and buybacks. In addition to increasing its dividend by 35% Thursday, AbbVie announced a new $10 billion ... | Rova-T, a solid-tumor cancer drug, upadicitinib, a rheumatoid arthritis drug, and risankizumab, a psoriasis drug are the three most exciting potential blockbuster drugs in AbbVie's pipeline. Given the additional clarity into Humira's future, a stable of fast-growing drugs, and multiple blockbusters making their way to ... | Given the additional clarity into Humira's future, a stable of fast-growing drugs, and multiple blockbusters making their way to market, AbbVie should have plenty of cash flow coming in to support dividend payments and buybacks. In addition to increasing its dividend by 35% Thursday, AbbVie announced a new $10 billion ... |
25,661 | 2018-02-15 00:00:00 UTC | AbbVie Stock Rises After Increasing Dividend By 35% | ABBV | https://www.nasdaq.com/articles/abbvie-stock-rises-after-increasing-dividend-35-2018-02-15 | null | null | AbbVie ( ABBV ) shares climbed Thursday after the biopharma announced it would raise its dividend by 35% to 96 cents per share and authorized a new $10 billion stock repurchase program. The dividend increased from 71 cents per share.
[ibd-display-video id=3149582 width=50 float=left autostart=true] Piper Jaffray analys... | The cash dividend is payable May 15 to stockholders of record at the close of business on April 13, AbbVie said in a news release. In after-hours trading on the stock market today , AbbVie rose a fraction after advancing 1.6% during the regular session, to 114.90. AbbVie ( ABBV ) shares climbed Thursday after the bioph... | "After an unexpected (and somewhat alarming) midday trading halt, AbbVie announced its board-approved plans for deployment of capital following U.S. tax reform, which will include $10 billion in additional share repurchase authorization and a 35% dividend increase," he said in a note to clients. AbbVie ( ABBV ) shares ... | AbbVie ( ABBV ) shares climbed Thursday after the biopharma announced it would raise its dividend by 35% to 96 cents per share and authorized a new $10 billion stock repurchase program. "After an unexpected (and somewhat alarming) midday trading halt, AbbVie announced its board-approved plans for deployment of capital ... | [ibd-display-video id=3149582 width=50 float=left autostart=true] Piper Jaffray analyst Christopher Raymond boosted his price target on AbbVie to 138 from 130, and kept his overweight rating. The news follows AbbVie's guidance for a 9% tax rate in 2018 following U.S. tax reform. "After an unexpected (and somewhat alarm... |
25,662 | 2018-02-15 00:00:00 UTC | 6 Healthcare Stocks We Think Deserve Gold Medals (Hint: One's a Marijuana Stock) | ABBV | https://www.nasdaq.com/articles/6-healthcare-stocks-we-think-deserve-gold-medals-hint-ones-marijuana-stock-2018-02-15 | null | null | The U.S. won its 100th gold medal in Winter Olympics history this week, and that got us thinking: If there were an Olympics for healthcare companies, who would be the winners?
To find out, we asked The Motley Fool's Industry Focus: Healthcare analyst Kristine Harjes and healthcare specialist Todd Campbell to pick winne... | To find out, we asked The Motley Fool's Industry Focus: Healthcare analyst Kristine Harjes and healthcare specialist Todd Campbell to pick winners across six categories: Best dividend stock Best financial fortitude stock Best marijuana stock Best healthcare IT stock Best blue-chip biotech stock Best international healt... | To find out, we asked The Motley Fool's Industry Focus: Healthcare analyst Kristine Harjes and healthcare specialist Todd Campbell to pick winners across six categories: Best dividend stock Best financial fortitude stock Best marijuana stock Best healthcare IT stock Best blue-chip biotech stock Best international healt... | To find out, we asked The Motley Fool's Industry Focus: Healthcare analyst Kristine Harjes and healthcare specialist Todd Campbell to pick winners across six categories: Best dividend stock Best financial fortitude stock Best marijuana stock Best healthcare IT stock Best blue-chip biotech stock Best international healt... | To find out, we asked The Motley Fool's Industry Focus: Healthcare analyst Kristine Harjes and healthcare specialist Todd Campbell to pick winners across six categories: Best dividend stock Best financial fortitude stock Best marijuana stock Best healthcare IT stock Best blue-chip biotech stock Best international healt... |
25,663 | 2018-02-14 00:00:00 UTC | 3 Top Stocks You Can Buy and Hold for the Next Decade | ABBV | https://www.nasdaq.com/articles/3-top-stocks-you-can-buy-and-hold-next-decade-2018-02-14 | null | null | Warren Buffett once said, "If you aren't willing to own a stock for 10 years, don't even think about owning it for 10 minutes. Put together a portfolio of companies whose aggregate earnings march upward over the years, and so also will the portfolio's market value." As is usually the case, Buffett was right.
There are ... | And while the autoimmune disease drug will face biosimilar competition in the U.S. in 2023 (and in Europe later this year), Humira is likely to continue generating plenty of revenue for AbbVie well into the next decade. While AbbVie's earnings growth from these drugs seem likely to push the stock higher, there's also a... | I think AbbVie (NYSE: ABBV) , NVIDIA (NASDAQ: NVDA) , and The Walt Disney Company (NYSE: DIS) fit in that group and especially stand out as three of the top stocks you can buy and hold for the next decade. AbbVie I view AbbVie as the best big pharma stock on the market right now. AbbVie has a good shot at keeping its N... | I think AbbVie (NYSE: ABBV) , NVIDIA (NASDAQ: NVDA) , and The Walt Disney Company (NYSE: DIS) fit in that group and especially stand out as three of the top stocks you can buy and hold for the next decade. While AbbVie's earnings growth from these drugs seem likely to push the stock higher, there's also another reason ... | AbbVie I view AbbVie as the best big pharma stock on the market right now. While AbbVie's earnings growth from these drugs seem likely to push the stock higher, there's also another reason behind the company's tremendous total shareholder return of more than 270% over the last five years: its dividend. I think AbbVie (... |
25,664 | 2018-02-14 00:00:00 UTC | MTUM, BA, ABBV, C: ETF Inflow Alert | ABBV | https://www.nasdaq.com/articles/mtum-ba-abbv-c-etf-inflow-alert-2018-02-14 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Edge MSCI USA Momentum Factor ETF (Symbol: MTUM) where we have detected an approximate $132.8 million dollar inflow -- that's a 1.9% increase week over week in outstanding units (fr... | Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is up about 1%, AbbVie Inc (Symbol: ABBV) is up about 0.5%, and Citigroup Inc (Symbol: C) is up by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one stan... | Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is up about 1%, AbbVie Inc (Symbol: ABBV) is up about 0.5%, and Citigroup Inc (Symbol: C) is up by about 0.2%. For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one year price performance of... | Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is up about 1%, AbbVie Inc (Symbol: ABBV) is up about 0.5%, and Citigroup Inc (Symbol: C) is up by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one stan... | Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is up about 1%, AbbVie Inc (Symbol: ABBV) is up about 0.5%, and Citigroup Inc (Symbol: C) is up by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one stan... |
25,665 | 2018-02-14 00:00:00 UTC | Lilly's Taltz Positive in Phase III Label Expansion Study | ABBV | https://www.nasdaq.com/articles/lillys-taltz-positive-in-phase-iii-label-expansion-study-2018-02-14 | null | null | Eli Lilly and CompanyLLY announced positive top-line data from a phase III label expansion study evaluating its psoriasis drug, Taltz (ixekizumab), in patients with ankylosing spondylitis ("AS"). The drug met the primary endpoint of improvement in the signs and symptoms of AS and all secondary endpoints as well.
Taltz,... | The study consisted of a placebo arm and an active control arm with AbbVie's ABBV arthritis drug, Humira. Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Ana... | Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report To read this article on Zacks.com click here. The study consisted of a placebo arm and an act... | Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report To read this article on Zacks.com click here. The study consisted of a placebo arm and an act... | The study consisted of a placebo arm and an active control arm with AbbVie's ABBV arthritis drug, Humira. Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Ana... |
25,666 | 2018-02-13 00:00:00 UTC | Zacks.com highlights: Jones Lang LaSalle, Intel, Dollar General, AbbVie and Owens Corning | ABBV | https://www.nasdaq.com/articles/zacks.com-highlights%3A-jones-lang-lasalle-intel-dollar-general-abbvie-and-owens-corning | null | null | For Immediate Release
Chicago, IL - Feb 13, 2018 - Stocks in this week's article include: Jones Lang LaSalleInc.JLL , IntelINTC , Dollar General CorporationDG , AbbVie Inc.ABBV and Owens Corning Inc.OC .
Screen of the Week of Zacks Investment Research:
5 Solid Dividend Growth Stocks Amid Rising Rates
Rising yields have... | For Immediate Release Chicago, IL - Feb 13, 2018 - Stocks in this week's article include: Jones Lang LaSalleInc.JLL , IntelINTC , Dollar General CorporationDG , AbbVie Inc.ABBV and Owens Corning Inc.OC . Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Owens Corning Inc (OC): Free Stock Anal... | For Immediate Release Chicago, IL - Feb 13, 2018 - Stocks in this week's article include: Jones Lang LaSalleInc.JLL , IntelINTC , Dollar General CorporationDG , AbbVie Inc.ABBV and Owens Corning Inc.OC . Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Owens Corning Inc (OC): Free Stock Anal... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Owens Corning Inc (OC): Free Stock Analysis Report Jones Lang LaSalle Incorporated (JLL): Free Stock Analysis Report Dollar General Corporation (DG): Free Stock Analysis Report Intel Corporation (INTC): Free Stock Analysis Report To read this ... | For Immediate Release Chicago, IL - Feb 13, 2018 - Stocks in this week's article include: Jones Lang LaSalleInc.JLL , IntelINTC , Dollar General CorporationDG , AbbVie Inc.ABBV and Owens Corning Inc.OC . Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Owens Corning Inc (OC): Free Stock Anal... |
25,667 | 2018-02-13 00:00:00 UTC | 3 Dividend Stocks for In-the-Know Investors | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-know-investors-2018-02-13 | null | null | Keeping track of every dividend-paying stock is tough, and as a result, many intriguing income stocks have probably fallen off your watch list. If that's true of Brookfield Renewable Partners (NYSE: BEP) , Store Capital (NYSE: STOR) , and AbbVie Inc. (NYSE: ABBV) , it might be time to look at them again. According to t... | The extra time is great news because AbbVie has a lot of late-stage drugs that could reach the market before Humira's sales begin to drop. If that's true of Brookfield Renewable Partners (NYSE: BEP) , Store Capital (NYSE: STOR) , and AbbVie Inc. (NYSE: ABBV) , it might be time to look at them again. Time for this incom... | If that's true of Brookfield Renewable Partners (NYSE: BEP) , Store Capital (NYSE: STOR) , and AbbVie Inc. (NYSE: ABBV) , it might be time to look at them again. Time for this income-friendly stock to be back on your radar Todd Campbell(AbbVie Inc.): Worry that its best-selling drug would soon face competition because ... | If that's true of Brookfield Renewable Partners (NYSE: BEP) , Store Capital (NYSE: STOR) , and AbbVie Inc. (NYSE: ABBV) , it might be time to look at them again. Time for this income-friendly stock to be back on your radar Todd Campbell(AbbVie Inc.): Worry that its best-selling drug would soon face competition because ... | If that's true of Brookfield Renewable Partners (NYSE: BEP) , Store Capital (NYSE: STOR) , and AbbVie Inc. (NYSE: ABBV) , it might be time to look at them again. Time for this income-friendly stock to be back on your radar Todd Campbell(AbbVie Inc.): Worry that its best-selling drug would soon face competition because ... |
25,668 | 2018-02-13 00:00:00 UTC | Better Buy: Eli Lilly and Company vs. Johnson & Johnson | ABBV | https://www.nasdaq.com/articles/better-buy-eli-lilly-and-company-vs-johnson-johnson-2018-02-13 | null | null | If you had bought $10,000 of Eli Lilly and Company (NYSE: LLY) stock 10 years ago and held it, your initial investment would now be worth roughly $22,660 with dividends reinvested. However, if you had used the same amount of money to buy and hold Johnson & Johnson (NYSE: JNJ) stock, you would be sitting on close to $28... | The company's oncology products include Imbruvica, which J&J co-markets with AbbVie , and Darzalex. *Stock Advisor returns as of February 5, 2018 Keith Speights owns shares of AbbVie and Pfizer. If you had bought $10,000 of Eli Lilly and Company (NYSE: LLY) stock 10 years ago and held it, your initial investment would ... | The company's oncology products include Imbruvica, which J&J co-markets with AbbVie , and Darzalex. *Stock Advisor returns as of February 5, 2018 Keith Speights owns shares of AbbVie and Pfizer. The case for Johnson & Johnson Johnson & Johnson isn't just a big pharma; it's a big consumer healthcare and big medical devi... | The company's oncology products include Imbruvica, which J&J co-markets with AbbVie , and Darzalex. *Stock Advisor returns as of February 5, 2018 Keith Speights owns shares of AbbVie and Pfizer. The case for Johnson & Johnson Johnson & Johnson isn't just a big pharma; it's a big consumer healthcare and big medical devi... | The company's oncology products include Imbruvica, which J&J co-markets with AbbVie , and Darzalex. *Stock Advisor returns as of February 5, 2018 Keith Speights owns shares of AbbVie and Pfizer. Which of these big pharma stocks is the better pick for investors now? |
25,669 | 2018-02-12 00:00:00 UTC | 5 Solid Dividend Growth Stocks Amid Rising Rates | ABBV | https://www.nasdaq.com/articles/5-solid-dividend-growth-stocks-amid-rising-rates-2018-02-12-0 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Rising yields have dampened the appeal for dividend stocks. Although high dividend stocks are an eye soar in the current environment, dividend growth ones pose strong fundamentals and are lucrative, especially given the new tax legislation in the United Sta... | The stock has a Zacks Rank #2 and a Growth Score of B. Illinois-based AbbVie Inc (NYSE: ABBV ) is a global research-based biopharmaceutical company, which discovers, develops, manufactures and sells pharmaceutical products worldwide. The stock has a Zacks Rank #2 and a Growth Score of B. Tennessee-based Dollar General ... | The stock has a Zacks Rank #2 and a Growth Score of B. Illinois-based AbbVie Inc (NYSE: ABBV ) is a global research-based biopharmaceutical company, which discovers, develops, manufactures and sells pharmaceutical products worldwide. 5-Year Historical EPS Growth greater than zero: This represents stocks with a solid ea... | The stock has a Zacks Rank #2 and a Growth Score of B. Illinois-based AbbVie Inc (NYSE: ABBV ) is a global research-based biopharmaceutical company, which discovers, develops, manufactures and sells pharmaceutical products worldwide. 5 Mid-Cap Growth ETFs for a Roller-Coaster Market Moreover, a history of dividend grow... | The stock has a Zacks Rank #2 and a Growth Score of B. Illinois-based AbbVie Inc (NYSE: ABBV ) is a global research-based biopharmaceutical company, which discovers, develops, manufactures and sells pharmaceutical products worldwide. 5 Mid-Cap Growth ETFs for a Roller-Coaster Market Moreover, a history of dividend grow... |
25,670 | 2018-02-12 00:00:00 UTC | 5 Solid Dividend Growth Stocks Amid Rising Rates | ABBV | https://www.nasdaq.com/articles/5-solid-dividend-growth-stocks-amid-rising-rates-2018-02-12 | null | null | Rising yields have dampened the appeal for dividend stocks . Although high dividend stocks are an eye soar in the current environment, dividend growth ones pose strong fundamentals and are lucrative, especially given the new tax legislation in the United States and heightened volatility.
Why Dividend Growth?
Stocks tha... | The stock has a Zacks Rank #2 and a Growth Score of B. Illinois-based AbbVie Inc. ABBV is a global research-based biopharmaceutical company, which discovers, develops, manufactures and sells pharmaceutical products worldwide. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Owens Corning Inc... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Owens Corning Inc (OC): Free Stock Analysis Report Jones Lang LaSalle Incorporated (JLL): Free Stock Analysis Report Dollar General Corporation (DG): Free Stock Analysis Report Intel Corporation (INTC): Free Stock Analysis Report To read this ... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Owens Corning Inc (OC): Free Stock Analysis Report Jones Lang LaSalle Incorporated (JLL): Free Stock Analysis Report Dollar General Corporation (DG): Free Stock Analysis Report Intel Corporation (INTC): Free Stock Analysis Report To read this ... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Owens Corning Inc (OC): Free Stock Analysis Report Jones Lang LaSalle Incorporated (JLL): Free Stock Analysis Report Dollar General Corporation (DG): Free Stock Analysis Report Intel Corporation (INTC): Free Stock Analysis Report To read this ... |
25,671 | 2018-02-12 00:00:00 UTC | These 3 Drugs Are Critical to AbbVie's Success | ABBV | https://www.nasdaq.com/articles/these-3-drugs-are-critical-abbvies-success-2018-02-12 | null | null | AbbVie Inc. (NYSE: ABBV) won an important patent battle last fall that protects its cash cow, Humira, for a few more years; however, Humira will face off against biosimilars eventually, and that makes launching new drugs critical if it wants to continue growing. Can this company's research team deliver? While there are... | If Rova-T wins a regulatory nod in late-line small cell lung cancer and data from its other trials pan out, then AbbVie thinks it could be a multibillion-dollar drug because its addressable market could be big and there's a significant need for new treatment options for these patients. AbbVie Inc. (NYSE: ABBV) won an i... | Last year, AbbVie unveiled results from three phase 3 studies in rheumatoid arthritis, and success in those trials has the company planning to file for an FDA green light by the end of 2018, as long as two more RA trials that are expected to have data available soon pan out, too. AbbVie believes the results are good en... | If Rova-T wins a regulatory nod in late-line small cell lung cancer and data from its other trials pan out, then AbbVie thinks it could be a multibillion-dollar drug because its addressable market could be big and there's a significant need for new treatment options for these patients. Last year, AbbVie unveiled result... | Data from a third-line Rova-T study is expected in Q2 2018, and if it's good, then AbbVie plans to file for an accelerated approval. Last year, AbbVie unveiled results from three phase 3 studies in rheumatoid arthritis, and success in those trials has the company planning to file for an FDA green light by the end of 20... |
25,672 | 2018-02-12 00:00:00 UTC | Is AbbVie or Vertex Pharmaceuticals the Better Buy Now? | ABBV | https://www.nasdaq.com/articles/abbvie-or-vertex-pharmaceuticals-better-buy-now-2018-02-12 | null | null | AbbVie Inc. (NYSE: ABBV) and Vertex Pharmaceuticals (NASDAQ: VRTX) significantly outperformed the S&P 500 in 2017, but a stock market correction has caused their shares to drop. Both companies recently unveiled optimistic plans that suggest their sales and profits can continue climbing, so is now a good time to buy the... | AbbVie Inc. (NYSE: ABBV) and Vertex Pharmaceuticals (NASDAQ: VRTX) significantly outperformed the S&P 500 in 2017, but a stock market correction has caused their shares to drop. In this episode of The Motley Fool's Industry Focus: Healthcare , analyst Kristine Harjes and Motley Fool contributor Todd Campbell discuss th... | In this episode of The Motley Fool's Industry Focus: Healthcare , analyst Kristine Harjes and Motley Fool contributor Todd Campbell discuss the stock market's recent correction and what could be in store for AbbVie and Vertex Pharmaceuticals' investors. The other thing that makes me a little nervous about Vertex, and i... | In this episode of The Motley Fool's Industry Focus: Healthcare , analyst Kristine Harjes and Motley Fool contributor Todd Campbell discuss the stock market's recent correction and what could be in store for AbbVie and Vertex Pharmaceuticals' investors. AbbVie Inc. (NYSE: ABBV) and Vertex Pharmaceuticals (NASDAQ: VRTX)... | AbbVie Inc. (NYSE: ABBV) and Vertex Pharmaceuticals (NASDAQ: VRTX) significantly outperformed the S&P 500 in 2017, but a stock market correction has caused their shares to drop. In this episode of The Motley Fool's Industry Focus: Healthcare , analyst Kristine Harjes and Motley Fool contributor Todd Campbell discuss th... |
25,673 | 2018-02-11 00:00:00 UTC | 3 Top Healthcare Stocks to Buy in February | ABBV | https://www.nasdaq.com/articles/3-top-healthcare-stocks-buy-february-2018-02-11 | null | null | The recent market downturn has created some great buying opportunity for opportunistic healthcare investors. But which stocks can be safely purchased today? We asked a team of healthcare investors to weigh in, and they picked AbbVie (NYSE: ABBV) , Mylan Laboratories (NASDAQ: MYL) , IQVIA Holdings (NYSE: IQV) .
Everybod... | We asked a team of healthcare investors to weigh in, and they picked AbbVie (NYSE: ABBV) , Mylan Laboratories (NASDAQ: MYL) , IQVIA Holdings (NYSE: IQV) . Everybody can love this stock Keith Speights (AbbVie): Some stocks don't appeal to every kind of investor. However, I think AbbVie does. | We asked a team of healthcare investors to weigh in, and they picked AbbVie (NYSE: ABBV) , Mylan Laboratories (NASDAQ: MYL) , IQVIA Holdings (NYSE: IQV) . Everybody can love this stock Keith Speights (AbbVie): Some stocks don't appeal to every kind of investor. However, I think AbbVie does. | We asked a team of healthcare investors to weigh in, and they picked AbbVie (NYSE: ABBV) , Mylan Laboratories (NASDAQ: MYL) , IQVIA Holdings (NYSE: IQV) . Everybody can love this stock Keith Speights (AbbVie): Some stocks don't appeal to every kind of investor. However, I think AbbVie does. | However, I think AbbVie does. We asked a team of healthcare investors to weigh in, and they picked AbbVie (NYSE: ABBV) , Mylan Laboratories (NASDAQ: MYL) , IQVIA Holdings (NYSE: IQV) . Everybody can love this stock Keith Speights (AbbVie): Some stocks don't appeal to every kind of investor. |
25,674 | 2018-02-08 00:00:00 UTC | What Are the Best Healthcare Stocks to Buy? Here Are a Top AI System's 5 Favorites | ABBV | https://www.nasdaq.com/articles/what-are-best-healthcare-stocks-buy-here-are-top-ai-systems-5-favorites-2018-02-08 | null | null | What if a complex artificial-intelligence (AI) system could pick stocks for you? With the AI Powered Equity ETF (AIEQ) launched by Equbot, it can. Equbot used IBM Watson, one of the world's leading AI platforms, to try to identify stocks that would beat market returns with similar volatility levels as the overall marke... | The top five healthcare stocks AIEQ owns right now are Envision Healthcare (NYSE: EVHC) , Encompass Health , UnitedHealth Group (NYSE: UNH) , AbbVie (NYSE: ABBV) , and PDL BioPharma (NASDAQ: PDLI) . AbbVie AbbVie is one of the biggest biopharmaceutical companies on the market. My guess is that Equbot's AI system likes ... | The top five healthcare stocks AIEQ owns right now are Envision Healthcare (NYSE: EVHC) , Encompass Health , UnitedHealth Group (NYSE: UNH) , AbbVie (NYSE: ABBV) , and PDL BioPharma (NASDAQ: PDLI) . AbbVie AbbVie is one of the biggest biopharmaceutical companies on the market. My guess is that Equbot's AI system likes ... | The top five healthcare stocks AIEQ owns right now are Envision Healthcare (NYSE: EVHC) , Encompass Health , UnitedHealth Group (NYSE: UNH) , AbbVie (NYSE: ABBV) , and PDL BioPharma (NASDAQ: PDLI) . AbbVie AbbVie is one of the biggest biopharmaceutical companies on the market. My guess is that Equbot's AI system likes ... | The top five healthcare stocks AIEQ owns right now are Envision Healthcare (NYSE: EVHC) , Encompass Health , UnitedHealth Group (NYSE: UNH) , AbbVie (NYSE: ABBV) , and PDL BioPharma (NASDAQ: PDLI) . AbbVie AbbVie is one of the biggest biopharmaceutical companies on the market. My guess is that Equbot's AI system likes ... |
25,675 | 2018-02-08 00:00:00 UTC | Novartis' Cosentyx Label Expanded to Include Scalp Psoriasis | ABBV | https://www.nasdaq.com/articles/novartis-cosentyx-label-expanded-to-include-scalp-psoriasis-2018-02-08 | null | null | NovartisNVS announced that the FDA has approved a line extension for its IL-17A inhibitor drug, Cosentyx, in moderate-to-severe scalp psoriasis. The FDA approval comes on the back of positive efficacy and safety outcomes from a dedicated phase III study - SCALP - in patients with scalp psoriasis.
We note that the drug ... | Novartis is also conducting head-to-head clinical trials - EXCEED and SURPASS - to evaluate the superiority of Cosentyx versus AbbVie's ABBV Humira in PsA and to a proposed biosimilar of Humira in AS, respectively. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free... | Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Novartis is also conducting head-to-head clinical tri... | Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Novartis is also conducting head-to-head clinical tri... | Novartis is also conducting head-to-head clinical trials - EXCEED and SURPASS - to evaluate the superiority of Cosentyx versus AbbVie's ABBV Humira in PsA and to a proposed biosimilar of Humira in AS, respectively. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free... |
25,676 | 2018-02-08 00:00:00 UTC | FDA Approves Gilead (GILD) HIV Triple Therapy, Stock Up | ABBV | https://www.nasdaq.com/articles/fda-approves-gilead-gild-hiv-triple-therapy-stock-up-2018-02-08 | null | null | Gilead Sciences, Inc.GILD received a major boost when the FDA approved the company's once-daily single tablet regimen ("STR"), Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF) for HIV-1 infection.
The approval, which comes ahead of the PDUFA date of Feb 12, 2018, provides a major ... | The HCV franchise has been under pressure for a while due to lower patient starts and increased competition form AbbVie's ABBV . Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Scienc... | Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. The HCV franchise has been under pressu... | Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. The HCV franchise has been under pressu... | The HCV franchise has been under pressure for a while due to lower patient starts and increased competition form AbbVie's ABBV . Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Scienc... |
25,677 | 2018-02-07 00:00:00 UTC | Add These 7 GARP Stocks to Your Portfolio for Better Returns | ABBV | https://www.nasdaq.com/articles/add-these-7-garp-stocks-to-your-portfolio-for-better-returns-2018-02-07 | null | null | Growth at a reasonable price or GARP is an excellent way for investors to make some quick gains. This strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount.
The GARP approach leads to the identification of stocks that are priced below the market or any reasonable ... | AbbVie Inc . ABBV is a global, research-based biopharmaceutical company. Click to get this free report MSCI Inc (MSCI): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Home Depot, Inc. (The) (HD): Free Stock Analysis Report Lazard Ltd. (LAZ): Free Stock Analysis Report First American Corporati... | Click to get this free report MSCI Inc (MSCI): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Home Depot, Inc. (The) (HD): Free Stock Analysis Report Lazard Ltd. (LAZ): Free Stock Analysis Report First American Corporation (The) (FAF): Free Stock Analysis Report American Financial Group, Inc.... | Click to get this free report MSCI Inc (MSCI): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Home Depot, Inc. (The) (HD): Free Stock Analysis Report Lazard Ltd. (LAZ): Free Stock Analysis Report First American Corporation (The) (FAF): Free Stock Analysis Report American Financial Group, Inc.... | AbbVie Inc . ABBV is a global, research-based biopharmaceutical company. Click to get this free report MSCI Inc (MSCI): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Home Depot, Inc. (The) (HD): Free Stock Analysis Report Lazard Ltd. (LAZ): Free Stock Analysis Report First American Corporati... |
25,678 | 2018-02-07 00:00:00 UTC | Gilead (GILD) Beats on Q4 Earnings, 2018 View Lacks Lustre | ABBV | https://www.nasdaq.com/articles/gilead-gild-beats-on-q4-earnings-2018-view-lacks-lustre-2018-02-07 | null | null | Gilead Sciences, Inc.'sGILD reported fourth-quarter 2017 results wherein both earnings and revenues surpassed expectations. However, management issued a bleak view for 2018.
Consequently, the stock declined in after-market hours trading and is expected to open in the red given the expectation of a further decline in he... | We note that Harvoni, Sovaldi and Epclusa, face competition from AbbVie's ABBV Viekira Pak and Viekira XR, Bristol-Myers' BMY and Merck's MRK Zepatier. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV):... | We note that Harvoni, Sovaldi and Epclusa, face competition from AbbVie's ABBV Viekira Pak and Viekira XR, Bristol-Myers' BMY and Merck's MRK Zepatier. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV):... | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Harvoni,... | We note that Harvoni, Sovaldi and Epclusa, face competition from AbbVie's ABBV Viekira Pak and Viekira XR, Bristol-Myers' BMY and Merck's MRK Zepatier. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV):... |
25,679 | 2018-02-07 00:00:00 UTC | Why AbbVie Inc.'s Shares Rocketed 16% in January | ABBV | https://www.nasdaq.com/articles/why-abbvie-incs-shares-rocketed-16-january-2018-02-07 | null | null | What happened
After updating investors on its 2017 financial performance and providing a bullish outlook for its future, shares in AbbVie Inc. (NYSE: ABBV) rallied by 16% in January, according to S&P Global Market Intelligence .
So what
Investors are less nervous about generic competition to AbbVie's best-selling drug,... | What happened After updating investors on its 2017 financial performance and providing a bullish outlook for its future, shares in AbbVie Inc. (NYSE: ABBV) rallied by 16% in January, according to S&P Global Market Intelligence . So what Investors are less nervous about generic competition to AbbVie's best-selling drug,... | So what Investors are less nervous about generic competition to AbbVie's best-selling drug, Humira, following a bullish outlook from management at the J.P. Morgan healthcare conference last month. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Na... | In 2018, AbbVie thinks that growing demand for Mavyret, its hepatitis C drug, will add more than $1 billion to sales and that Imbruvica, a chronic lymphocytic leukemia drug, will continue to make headway toward its long-term goal of $7 billion per year in revenue. 10 stocks we like better than AbbVie When investing gen... | Since it was spun out as its own company in 2013, AbbVie's increased its dividend by 77%. What happened After updating investors on its 2017 financial performance and providing a bullish outlook for its future, shares in AbbVie Inc. (NYSE: ABBV) rallied by 16% in January, according to S&P Global Market Intelligence . S... |
25,680 | 2018-02-07 00:00:00 UTC | Why AbbVie is a Top 25 Dividend Giant (ABBV) | ABBV | https://www.nasdaq.com/articles/why-abbvie-top-25-dividend-giant-abbv-2018-02-07 | null | null | AbbVie Inc (Symbol: ABBV) has been named as a Top 25 ''Dividend Giant'' by ETF Channel , with a staggering $16.30B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 2.55% yield, according to the most recent Dividend Channel''DividendRank'' report. The report noted a strong qu... | AbbVie Inc (Symbol: ABBV) has been named as a Top 25 ''Dividend Giant'' by ETF Channel , with a staggering $16.30B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 2.55% yield, according to the most recent Dividend Channel''DividendRank'' report. The report noted a strong qu... | AbbVie Inc (Symbol: ABBV) has been named as a Top 25 ''Dividend Giant'' by ETF Channel , with a staggering $16.30B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 2.55% yield, according to the most recent Dividend Channel''DividendRank'' report. The report noted a strong qu... | AbbVie Inc (Symbol: ABBV) has been named as a Top 25 ''Dividend Giant'' by ETF Channel , with a staggering $16.30B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 2.55% yield, according to the most recent Dividend Channel''DividendRank'' report. The annualized dividend paid... | The report noted a strong quarterly dividend history at AbbVie Inc, and favorable long-term multi-year growth rates in key fundamental data points. The annualized dividend paid by AbbVie Inc is $2.84/share, currently paid in quarterly installments, and its most recent dividend ex-date was on 01/11/2018. AbbVie Inc (Sym... |
25,681 | 2018-02-07 00:00:00 UTC | Gilead Sciences Inc. Delivers Deja Vu in the Fourth Quarter | ABBV | https://www.nasdaq.com/articles/gilead-sciences-inc-delivers-deja-vu-fourth-quarter-2018-02-07 | null | null | When Gilead Sciences (NASDAQ: GILD) reported its third-quarter results in October, three things jumped out. First, the biotech's hepatitis C virus (HCV) franchise continued to struggle. Second, Gilead's HIV franchise continued to dominate. And third, the company's cash position looked great.
Gilead announced its fourth... | Competition from AbbVie 's new HCV drug Mavyret appeared to make a significant dent in sales for Gilead's drug in the U.S. *Stock Advisor returns as of Feb. 5, 2018 Keith Speights owns shares of AbbVie and Gilead Sciences. The only bright spot for Gilead's HCV franchise was Vosevi, which made $170 million in the fourth... | Competition from AbbVie 's new HCV drug Mavyret appeared to make a significant dent in sales for Gilead's drug in the U.S. *Stock Advisor returns as of Feb. 5, 2018 Keith Speights owns shares of AbbVie and Gilead Sciences. Total HCV franchise revenue for the fourth quarter dropped from $3.2 billion in the prior-year pe... | Competition from AbbVie 's new HCV drug Mavyret appeared to make a significant dent in sales for Gilead's drug in the U.S. *Stock Advisor returns as of Feb. 5, 2018 Keith Speights owns shares of AbbVie and Gilead Sciences. Gilead Sciences results: The raw numbers Data source: Gilead Sciences. | Competition from AbbVie 's new HCV drug Mavyret appeared to make a significant dent in sales for Gilead's drug in the U.S. *Stock Advisor returns as of Feb. 5, 2018 Keith Speights owns shares of AbbVie and Gilead Sciences. While Gilead took this one-time hit, the company will be in better shape going forward, thanks to... |
25,682 | 2018-02-07 00:00:00 UTC | Wednesday's ETF with Unusual Volume: PPH | ABBV | https://www.nasdaq.com/articles/wednesdays-etf-unusual-volume-pph-2018-02-07 | null | null | The Pharmaceutical ETF ( PPH ) is seeing unusually high volume in afternoon trading Wednesday, with over 759,000 shares traded versus three month average volume of about 96,000. Shares of PPH were off about 0.1% on the day.
Components of that ETF with the highest volume on Wednesday were Pfizer ( PFE ), trading down ab... | Abbvie ( ABBV ) is the component faring the best Wednesday, higher by about 2.7% on the day, while Sanofi ( SNY ) is lagging other components of the Pharmaceutical ETF, trading lower by about 3.5%. The Pharmaceutical ETF ( PPH ) is seeing unusually high volume in afternoon trading Wednesday, with over 759,000 shares tr... | Abbvie ( ABBV ) is the component faring the best Wednesday, higher by about 2.7% on the day, while Sanofi ( SNY ) is lagging other components of the Pharmaceutical ETF, trading lower by about 3.5%. The Pharmaceutical ETF ( PPH ) is seeing unusually high volume in afternoon trading Wednesday, with over 759,000 shares tr... | Abbvie ( ABBV ) is the component faring the best Wednesday, higher by about 2.7% on the day, while Sanofi ( SNY ) is lagging other components of the Pharmaceutical ETF, trading lower by about 3.5%. The Pharmaceutical ETF ( PPH ) is seeing unusually high volume in afternoon trading Wednesday, with over 759,000 shares tr... | Abbvie ( ABBV ) is the component faring the best Wednesday, higher by about 2.7% on the day, while Sanofi ( SNY ) is lagging other components of the Pharmaceutical ETF, trading lower by about 3.5%. The Pharmaceutical ETF ( PPH ) is seeing unusually high volume in afternoon trading Wednesday, with over 759,000 shares tr... |
25,683 | 2018-02-06 00:00:00 UTC | Centene (CNC) Beats Q4 Earnings & Revenues, Ups '18 View | ABBV | https://www.nasdaq.com/articles/centene-cnc-beats-q4-earnings-revenues-ups-18-view-2018-02-06 | null | null | Centene Inc.CNC reported fourth-quarter 2017 adjusted net income per share of 97 cents, which beat the Zacks Consensus Estimate by 3.2%. Earnings, however, declined 18% year over year on higher expenses.
For the fourth quarter, total revenues grew 8% to $12.8 billion from the year-ago quarter, primarily driven by growt... | Among other players in the Medical sector that have reported their fourth-quarter earnings so far, AbbVie Inc. ABBV , UnitedHealth Group Incorporated UNH and Abbott Laboratories ABT have surpassed their respective Zacks Consensus Estimate. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Rep... | Among other players in the Medical sector that have reported their fourth-quarter earnings so far, AbbVie Inc. ABBV , UnitedHealth Group Incorporated UNH and Abbott Laboratories ABT have surpassed their respective Zacks Consensus Estimate. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Rep... | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Centene Corporation (CNC): Free Stock Analysis Report To read this article on Zacks.com click here. Among other players in ... | Among other players in the Medical sector that have reported their fourth-quarter earnings so far, AbbVie Inc. ABBV , UnitedHealth Group Incorporated UNH and Abbott Laboratories ABT have surpassed their respective Zacks Consensus Estimate. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Rep... |
25,684 | 2018-02-05 00:00:00 UTC | The Zacks Analyst Blog Highlights: Sanofi, Seattle Genetics, AbbVie, Celgene and Vertex | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-sanofi-seattle-genetics-abbvie-celgene-and-vertex-2018 | null | null | For Immediate Release
Chicago, IL - February 5, 2018 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include SanofiSNY , Seattle Genetic... | Here are highlights from Friday's Analyst Blog: Biotech Stock Roundup: ABBV, SNY, SGEN and More Acquisitions once again remained in focus this week with Ablynx agreeing to be acquired by Sanofi in a deal worth approximately €3.9 billion. Stocks recently featured in the blog include SanofiSNY , Seattle GeneticsSGEN , Ab... | Recap of the Week's Most Important Stories A Look at Q4 Earnings Results: Companies like Celgene, AbbVie, Biogen and Vertex reported fourth quarter results over the last five trading sessions. Click to get this free report Sanofi (SNY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Ph... | Click to get this free report Sanofi (SNY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Seattle Genetics, Inc. (SGEN): Free Stock Analysis Report To read this artic... | AbbVie is a Zacks Rank #2 (Buy) stock - you can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . Stocks recently featured in the blog include SanofiSNY , Seattle GeneticsSGEN , AbbVieABBV , CelgeneCELG and VertexVRTX . Here are highlights from Friday's Analyst Blog: Biotech Stock Roundup: ABBV,... |
25,685 | 2018-02-05 00:00:00 UTC | 3 Top Pharmaceutical Stocks to Buy Now | ABBV | https://www.nasdaq.com/articles/3-top-pharmaceutical-stocks-buy-now-2018-02-05 | null | null | Worldwide pharmaceutical sales were roughly $1 trillion in 2016, according to Statista. That's a massive number that should grow over time as the global population continues to age.
Given the market size and natural tailwind, it shouldn't be surprising that many pharma companies have grown to become truly gigantic. For... | Here's why Johnson & Johnson, AbbVie, and Bristol-Myers Squibb are my three favorites. AbbVie AbbVie's long-term success is attributable to a single name: Humira. In 2017 Humira hauled in about $18 billion in total sales and accounted for more than 60% of AbbVie's revenue. | Here's why Johnson & Johnson, AbbVie, and Bristol-Myers Squibb are my three favorites. AbbVie AbbVie's long-term success is attributable to a single name: Humira. In 2017 Humira hauled in about $18 billion in total sales and accounted for more than 60% of AbbVie's revenue. | Next, AbbVie plans to emphasize growth in its other top-selling drugs -- namely the cancer drug Imbruvica and the hepatitis C drug Mavyret -- as much as possible. Here's why Johnson & Johnson, AbbVie, and Bristol-Myers Squibb are my three favorites. AbbVie AbbVie's long-term success is attributable to a single name: Hu... | AbbVie AbbVie's long-term success is attributable to a single name: Humira. In 2017 Humira hauled in about $18 billion in total sales and accounted for more than 60% of AbbVie's revenue. Next, AbbVie plans to emphasize growth in its other top-selling drugs -- namely the cancer drug Imbruvica and the hepatitis C drug Ma... |
25,686 | 2018-02-05 00:00:00 UTC | Bristol-Myers (BMY) Beats on Q4 Earnings, Eliquis Impresses | ABBV | https://www.nasdaq.com/articles/bristol-myers-bmy-beats-on-q4-earnings-eliquis-impresses-2018-02-05 | null | null | Bristol-Myers Squibb Company 's BMY fourth-quarter 2017 earnings of 68 cents per share beat the Zacks Consensus Estimate of 67 cents and came ahead of the year-ago quarter earnings of 63 cents.
Moreover, total revenues of $5.45 billion surpassed the Zacks Consensus Estimate of $5.31 billion and increased from $5.24 bil... | Some better-ranked companies in the large-cap pharma industry are AbbVie Inc. ABBV , Pfizer Inc. PFE and H Lundbeck A/S HLUYY , each carrying a Zacks Rank #2 (Buy). Shares of AbbVie have gained 89.9% in the past year while earnings estimates for 2018 have gone up 9.9% over the past 30 days. Click to get this free repor... | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report H Lundbeck A/S (HLUYY): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked companies in the ... | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report H Lundbeck A/S (HLUYY): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked companies in the ... | Some better-ranked companies in the large-cap pharma industry are AbbVie Inc. ABBV , Pfizer Inc. PFE and H Lundbeck A/S HLUYY , each carrying a Zacks Rank #2 (Buy). Shares of AbbVie have gained 89.9% in the past year while earnings estimates for 2018 have gone up 9.9% over the past 30 days. Click to get this free repor... |
25,687 | 2018-02-04 00:00:00 UTC | 3 Headwinds in Q4 Earnings Results That Make Merck a Mediocre Stock | ABBV | https://www.nasdaq.com/articles/3-headwinds-q4-earnings-results-make-merck-mediocre-stock-2018-02-04 | null | null | Most of the headlines reporting Merck 's (NYSE: MRK) fourth-quarter and full-year 2017 results focused on the company's beating earnings estimates. Merck did indeed top estimates, announcing Q4 adjusted earnings per share of $0.98 -- well above the consensus analyst estimate of $0.94.
Despite this earnings beat, though... | However, newer HCV drugs from AbbVie and Gilead Sciences will almost certainly cause Zepatier's sales to fall drastically in 2018. *Stock Advisor returns as of January 2, 2018 Keith Speights owns shares of AbbVie, Gilead Sciences, and Pfizer. Most of the headlines reporting Merck 's (NYSE: MRK) fourth-quarter and full-... | However, newer HCV drugs from AbbVie and Gilead Sciences will almost certainly cause Zepatier's sales to fall drastically in 2018. *Stock Advisor returns as of January 2, 2018 Keith Speights owns shares of AbbVie, Gilead Sciences, and Pfizer. Here are three headwinds identified in the company's fourth-quarter earnings ... | However, newer HCV drugs from AbbVie and Gilead Sciences will almost certainly cause Zepatier's sales to fall drastically in 2018. *Stock Advisor returns as of January 2, 2018 Keith Speights owns shares of AbbVie, Gilead Sciences, and Pfizer. Here are three headwinds identified in the company's fourth-quarter earnings ... | However, newer HCV drugs from AbbVie and Gilead Sciences will almost certainly cause Zepatier's sales to fall drastically in 2018. *Stock Advisor returns as of January 2, 2018 Keith Speights owns shares of AbbVie, Gilead Sciences, and Pfizer. Most of the headlines reporting Merck 's (NYSE: MRK) fourth-quarter and full-... |
25,688 | 2018-02-04 00:00:00 UTC | What to Expect With Gilead Sciences' Q4 Results | ABBV | https://www.nasdaq.com/articles/what-expect-gilead-sciences-q4-results-2018-02-04 | null | null | It's been a familiar story for Gilead Sciences (NASDAQ: GILD) every time quarterly results roll around. The biotech reports solid growth for its HIV franchise. Its cash stockpile continues to get bigger and bigger. But slumping hepatitis C virus (HCV) sales pull down overall revenue and earnings.
Gilead will announce i... | In November, Gilead CEO John Milligan said he thought the launch of AbbVie 's (NYSE: ABBV) pan-genotypic HCV drug Mavyret set the stage "for smoothness in HCV sales for the future." AbbVie set a list price for Mavyret well below the list price of Gilead's Epclusa. AbbVie reported fourth-quarter results on Jan. 26. | AbbVie set a list price for Mavyret well below the list price of Gilead's Epclusa. In November, Gilead CEO John Milligan said he thought the launch of AbbVie 's (NYSE: ABBV) pan-genotypic HCV drug Mavyret set the stage "for smoothness in HCV sales for the future." AbbVie reported fourth-quarter results on Jan. 26. | In November, Gilead CEO John Milligan said he thought the launch of AbbVie 's (NYSE: ABBV) pan-genotypic HCV drug Mavyret set the stage "for smoothness in HCV sales for the future." AbbVie set a list price for Mavyret well below the list price of Gilead's Epclusa. AbbVie reported fourth-quarter results on Jan. 26. | AbbVie reported fourth-quarter results on Jan. 26. In November, Gilead CEO John Milligan said he thought the launch of AbbVie 's (NYSE: ABBV) pan-genotypic HCV drug Mavyret set the stage "for smoothness in HCV sales for the future." AbbVie set a list price for Mavyret well below the list price of Gilead's Epclusa. |
25,689 | 2018-02-03 00:00:00 UTC | 3 Top Orphan-Drug Stocks to Buy Now | ABBV | https://www.nasdaq.com/articles/3-top-orphan-drug-stocks-buy-now-2018-02-03 | null | null | Since 1983, the U.S. Food and Drug Administration has granted orphan-drug designation to over 3,500 drugs. This designation provides incentives to companies developing drugs and biologics for rare diseases and conditions, with "rare" generally meaning a disease affecting fewer than 200,000 patients in the United States... | Here's why I'd put AbbVie (NYSE: ABBV) , Celgene (NASDAQ: CELG) , and Vertex Pharmaceuticals (NASDAQ: VRTX) at the top of the list. AbbVie AbbVie claims one of the current top-selling orphan drugs -- Imbruvica. In 2017, Imbruvica generated sales for AbbVie of nearly $2.6 billion. | Here's why I'd put AbbVie (NYSE: ABBV) , Celgene (NASDAQ: CELG) , and Vertex Pharmaceuticals (NASDAQ: VRTX) at the top of the list. AbbVie AbbVie claims one of the current top-selling orphan drugs -- Imbruvica. In 2017, Imbruvica generated sales for AbbVie of nearly $2.6 billion. | Here's why I'd put AbbVie (NYSE: ABBV) , Celgene (NASDAQ: CELG) , and Vertex Pharmaceuticals (NASDAQ: VRTX) at the top of the list. AbbVie AbbVie claims one of the current top-selling orphan drugs -- Imbruvica. In 2017, Imbruvica generated sales for AbbVie of nearly $2.6 billion. | Here's why I'd put AbbVie (NYSE: ABBV) , Celgene (NASDAQ: CELG) , and Vertex Pharmaceuticals (NASDAQ: VRTX) at the top of the list. AbbVie AbbVie claims one of the current top-selling orphan drugs -- Imbruvica. In 2017, Imbruvica generated sales for AbbVie of nearly $2.6 billion. |
25,690 | 2018-02-02 00:00:00 UTC | AstraZeneca (AZN) Beats on Q4 Earnings, Guides for 2018 | ABBV | https://www.nasdaq.com/articles/astrazeneca-azn-beats-on-q4-earnings-guides-for-2018-2018-02-02 | null | null | AstraZeneca plcAZN reported fourth-quarter 2017 core earnings of 65 cents per American Depositary Share (ADS), which beat the Zacks Consensus Estimate of 45 cents. Core earnings rose 13% year over year at constant exchange rates (CER). Higher product sales boosted profits in the quarter.
Total revenues rose 2% at CER t... | Astrazeneca PLC Price, Consensus and EPS Surprise Astrazeneca PLC Price, Consensus and EPS Surprise | Astrazeneca PLC Quote A better-ranked company in the large-cap pharma industry is AbbVie Inc. ABBV , carrying a Zacks Rank #1. Shares of AbbVie are up 16.4% while earnings estimates for 2018 have gone up 12.7% over the... | Astrazeneca PLC Price, Consensus and EPS Surprise Astrazeneca PLC Price, Consensus and EPS Surprise | Astrazeneca PLC Quote A better-ranked company in the large-cap pharma industry is AbbVie Inc. ABBV , carrying a Zacks Rank #1. Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Merck & Com... | Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Incyte Corporation (INCY): Free Stock Analysis Report To read this article on Zacks.com click here. Astrazeneca PLC Price, Consensus and ... | Astrazeneca PLC Price, Consensus and EPS Surprise Astrazeneca PLC Price, Consensus and EPS Surprise | Astrazeneca PLC Quote A better-ranked company in the large-cap pharma industry is AbbVie Inc. ABBV , carrying a Zacks Rank #1. Shares of AbbVie are up 16.4% while earnings estimates for 2018 have gone up 12.7% over the... |
25,691 | 2018-02-02 00:00:00 UTC | 3 Top Biotherapeutics Stocks to Buy Now | ABBV | https://www.nasdaq.com/articles/3-top-biotherapeutics-stocks-buy-now-2018-02-02 | null | null | There are fewer true biotherapeutics available than you might think. Biotherapeutics, also known as biologics, include any type of medical treatment that is either produced by or involves living cells. In 2017, the U.S. Food and Drug Administration approved 22 biotherapeutics, and that was an increase from the 15 bioth... | Here's why I think AbbVie (NYSE: ABBV) , Celgene (NASDAQ: CELG) , and Gilead Sciences (NASDAQ: GILD) are top biotherapeutics stocks to buy right now. AbbVie There's no more successful biotherapeutic on the market than AbbVie's Humira. However, AbbVie expects to fend off potential rivals in the U.S. for several more yea... | Here's why I think AbbVie (NYSE: ABBV) , Celgene (NASDAQ: CELG) , and Gilead Sciences (NASDAQ: GILD) are top biotherapeutics stocks to buy right now. AbbVie There's no more successful biotherapeutic on the market than AbbVie's Humira. However, AbbVie expects to fend off potential rivals in the U.S. for several more yea... | Here's why I think AbbVie (NYSE: ABBV) , Celgene (NASDAQ: CELG) , and Gilead Sciences (NASDAQ: GILD) are top biotherapeutics stocks to buy right now. AbbVie There's no more successful biotherapeutic on the market than AbbVie's Humira. However, AbbVie expects to fend off potential rivals in the U.S. for several more yea... | AbbVie There's no more successful biotherapeutic on the market than AbbVie's Humira. Here's why I think AbbVie (NYSE: ABBV) , Celgene (NASDAQ: CELG) , and Gilead Sciences (NASDAQ: GILD) are top biotherapeutics stocks to buy right now. However, AbbVie expects to fend off potential rivals in the U.S. for several more yea... |
25,692 | 2018-02-02 00:00:00 UTC | 5 Top Earnings Growth Stocks to Buy in February | ABBV | https://www.nasdaq.com/articles/5-top-earnings-growth-stocks-buy-february-2018-02-02 | null | null | Since we have entered the Q4 reporting cycle, looking for stocks with unswerving earnings growth is the highest priority for astute investors. And why not? If the company doesn't make money, it won't last over the long haul. Consider a company's revenues over a given period of time, subtract the cost of production and ... | AbbVieABBV discovers, develops, manufactures and sells pharmaceutical products worldwide. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report State Bank Financial Corporation. Earnings estimates embody analysts' opinions of factors such as sales growth, product demand, competitive industry envi... | AbbVieABBV discovers, develops, manufactures and sells pharmaceutical products worldwide. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report State Bank Financial Corporation. Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and... | AbbVieABBV discovers, develops, manufactures and sells pharmaceutical products worldwide. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report State Bank Financial Corporation. Earnings Estimates Shape Share Prices We have often seen a decline in the stock price despite earnings growth and a ral... | AbbVieABBV discovers, develops, manufactures and sells pharmaceutical products worldwide. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report State Bank Financial Corporation. Earnings estimates embody analysts' opinions of factors such as sales growth, product demand, competitive industry envi... |
25,693 | 2018-02-02 00:00:00 UTC | Gilead's (GILD) HCV Segment to Decline Further in Q4 Earnings? | ABBV | https://www.nasdaq.com/articles/gileads-gild-hcv-segment-to-decline-further-in-q4-earnings-2018-02-02 | null | null | Biotech bigwig Gilead Sciences Inc.GILD develops drugs for the treatment of human immunodeficiency virus ("HIV"), liver diseases such as chronic hepatitis C virus ("HCV") infection and chronic hepatitis B virus ("HBV") infection, cardiovascular, hematology/oncology and inflammation/respiratory diseases.
Apart from bloc... | Harvoni and Sovaldi have been facing competition from AbbVie's ABBV Viekira Pak and Viekira XR and Merck's MRK Zepatier. Click to get this free report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Exelixis,... | Click to get this free report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report To read this article on Zacks.com click here. Harvoni and Sovaldi have been faci... | Click to get this free report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report To read this article on Zacks.com click here. Harvoni and Sovaldi have been faci... | Harvoni and Sovaldi have been facing competition from AbbVie's ABBV Viekira Pak and Viekira XR and Merck's MRK Zepatier. Click to get this free report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Exelixis,... |
25,694 | 2018-02-01 00:00:00 UTC | 5 Best Performing Stocks of January | ABBV | https://www.nasdaq.com/articles/5-best-performing-stocks-january-2018-02-01 | null | null | Markets started the New Year on a strong note, posting fresh records on multiple occasions. Newly instituted tax cuts had a beneficial impact on stocks with the Dow breaching the 25,000 and 26,000 mark in the same month. Economic data remained strong even as fourth-quarter earnings promised to be the most bullish in re... | Intel Corporation INTC , AbbVie Inc. ABBV and Honeywell International Inc. HON also posted encouraging earnings numbers. Click to get this free report J P Morgan Chase & Co (JPM): Free Stock Analysis Report U.S. Bancorp (USB): Free Stock Analysis Report Bank of America Corporation (BAC): Free Stock Analysis Report Petr... | Click to get this free report J P Morgan Chase & Co (JPM): Free Stock Analysis Report U.S. Bancorp (USB): Free Stock Analysis Report Bank of America Corporation (BAC): Free Stock Analysis Report Petroleo Brasileiro S.A.- Petrobras (PBR): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Honeywel... | Click to get this free report J P Morgan Chase & Co (JPM): Free Stock Analysis Report U.S. Bancorp (USB): Free Stock Analysis Report Bank of America Corporation (BAC): Free Stock Analysis Report Petroleo Brasileiro S.A.- Petrobras (PBR): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Honeywel... | Intel Corporation INTC , AbbVie Inc. ABBV and Honeywell International Inc. HON also posted encouraging earnings numbers. Click to get this free report J P Morgan Chase & Co (JPM): Free Stock Analysis Report U.S. Bancorp (USB): Free Stock Analysis Report Bank of America Corporation (BAC): Free Stock Analysis Report Petr... |
25,695 | 2018-02-01 00:00:00 UTC | Will Gilead (GILD) Disappoint Investors in Q4 Earnings? | ABBV | https://www.nasdaq.com/articles/will-gilead-gild-disappoint-investors-in-q4-earnings-2018-02-01 | null | null | Gilead Sciences Inc . GILD , is scheduled to report fourth-quarter results on Feb 6, after the market closes .
Gilead, a leader in the hepatitis C virus ("HCV") space, has a mixed track record, with the company beating estimates in three of the last four and missing in one. Last quarter, the company beat expectations b... | Harvoni and Sovaldi has been facing competition from AbbVie Inc.'s ABBV Viekira Pak and Viekira XR among others. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Anthera ... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Anthera Pharmaceuticals, Inc. (ANTH): Free Stock Analysis Report To read this article on Zacks.com click here. Harvoni an... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Anthera Pharmaceuticals, Inc. (ANTH): Free Stock Analysis Report To read this article on Zacks.com click here. Harvoni an... | Harvoni and Sovaldi has been facing competition from AbbVie Inc.'s ABBV Viekira Pak and Viekira XR among others. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Anthera ... |
25,696 | 2018-02-01 00:00:00 UTC | Biotech Stock Roundup: AbbVie 4Q Results Impress, Ablynx to be Acquired by Sanofi | ABBV | https://www.nasdaq.com/articles/biotech-stock-roundup-abbvie-4q-results-impress-ablynx-be-acquired-sanofi-2018-02-01 | null | null | Acquisitions once again remained in focus this week with Ablynx agreeing to be acquired by Sanofi SNY in a deal worth approximately €3.9 billion. Seattle Genetics SGEN also announced its intention to acquire Cascadian Therapeutics for about $614 million. Meanwhile, earnings results were in focus with AbbVie ABBV report... | Meanwhile, earnings results were in focus with AbbVie ABBV reporting a strong quarter and providing an upbeat outlook for 2018. Recap of the Week's Most Important Stories A Look at Q4 Earnings Results: Companies like Celgene CELG , AbbVie, Biogen and Vertex VRTX reported fourth quarter results over the last five tradin... | Recap of the Week's Most Important Stories A Look at Q4 Earnings Results: Companies like Celgene CELG , AbbVie, Biogen and Vertex VRTX reported fourth quarter results over the last five trading sessions. Click to get this free report Sanofi (SNY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Repor... | Click to get this free report Sanofi (SNY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Amgen Inc. (AMGN): ... | Meanwhile, earnings results were in focus with AbbVie ABBV reporting a strong quarter and providing an upbeat outlook for 2018. Recap of the Week's Most Important Stories A Look at Q4 Earnings Results: Companies like Celgene CELG , AbbVie, Biogen and Vertex VRTX reported fourth quarter results over the last five tradin... |
25,697 | 2018-01-31 00:00:00 UTC | The Zacks Analyst Blog Highlights: Bank of America, Citigroup, AbbVie, 3M, Starbucks and Halliburton | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-bank-of-america-citigroup-abbvie-3m-starbucks-and | null | null | For Immediate Release
Chicago, IL - Jan 31, 2018 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Bank of AmericaBAC , CitigroupC... | Stocks recently featured in the blog include Bank of AmericaBAC , CitigroupC , AbbVieABBV , 3MMMM , StarbucksSBUX and HalliburtonHAL . Here are highlights from Tuesday's Analyst Blog: Top Analyst Reports for Bank of America, Citigroup and AbbVie The Zacks Research Daily presents the best research output of our analyst ... | Today's Research Daily features new research reports on 16 major stocks, including Bank of America, Citigroup and AbbVie. Click to get this free report Citigroup Inc. (C): Free Stock Analysis Report Bank of America Corporation (BAC): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report 3M Company (... | Today's Research Daily features new research reports on 16 major stocks, including Bank of America, Citigroup and AbbVie. Click to get this free report Citigroup Inc. (C): Free Stock Analysis Report Bank of America Corporation (BAC): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report 3M Company (... | Today's Research Daily features new research reports on 16 major stocks, including Bank of America, Citigroup and AbbVie. Stocks recently featured in the blog include Bank of AmericaBAC , CitigroupC , AbbVieABBV , 3MMMM , StarbucksSBUX and HalliburtonHAL . Here are highlights from Tuesday's Analyst Blog: Top Analyst Re... |
25,698 | 2018-01-31 00:00:00 UTC | Lilly (LLY) Beats on Q4 Earnings, Raises 2018 EPS Guidance | ABBV | https://www.nasdaq.com/articles/lilly-lly-beats-on-q4-earnings-raises-2018-eps-guidance-2018-01-31 | null | null | Eli Lilly and CompanyLLY reported fourth-quarter 2017 adjusted earnings per share of $1.14, which beat the Zacks Consensus Estimate of $1.08 per share by 5.6%. Earnings rose 20% from the year-ago quarter backed by higher operating profits.
Revenues Beat
Quarterly revenues of $6.16 billion also beat the Zacks Consensus ... | A better-ranked stock in the pharma sector is AbbVie Inc. ABBV , carrying a Zacks Rank #2 (Buy). AbbVie's earnings estimates increased from $6.56 to $7.30 for 2018 over the last 30 days. Click to get this free report Sanofi (SNY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie... | Click to get this free report Sanofi (SNY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Incyte Corporation (INCY): Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock in the pharma sector is ... | Click to get this free report Sanofi (SNY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Incyte Corporation (INCY): Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock in the pharma sector is ... | A better-ranked stock in the pharma sector is AbbVie Inc. ABBV , carrying a Zacks Rank #2 (Buy). AbbVie's earnings estimates increased from $6.56 to $7.30 for 2018 over the last 30 days. Click to get this free report Sanofi (SNY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie... |
25,699 | 2018-01-31 00:00:00 UTC | Vertex Beats Views, Closes In On Cystic Fibrosis Treatments | ABBV | https://www.nasdaq.com/articles/vertex-beats-views-closes-cystic-fibrosis-treatments-2018-01-31 | null | null | Vertex Pharmaceuticals ( VRTX ) beat fourth-quarter sales expectations by more than 9% and has selected a pair of cystic fibrosis treatments to send into late-stage testing, the company said late Wednesday.
[ibd-display-video id=3117298 width=50 float=left autostart=true] Vertex reported adjusted income of 61 cents per... | AbbVie ( ABBV ) and Galapagos ( GLPG ) have also teamed up to make a triple-pill . Vertex Pharmaceuticals ( VRTX ) beat fourth-quarter sales expectations by more than 9% and has selected a pair of cystic fibrosis treatments to send into late-stage testing, the company said late Wednesday. "As we look at 2018 and beyond... | AbbVie ( ABBV ) and Galapagos ( GLPG ) have also teamed up to make a triple-pill . Of its total sales, Vertex brought in $621 million in revenue from cystic fibrosis treatments, growing 37% year over year. 90% Of Patients The triple-pill treatments are expected to treat up to 90% of cystic fibrosis patients, said Jeffr... | AbbVie ( ABBV ) and Galapagos ( GLPG ) have also teamed up to make a triple-pill . Of its total sales, Vertex brought in $621 million in revenue from cystic fibrosis treatments, growing 37% year over year. Pending additional data in the first half of the year, Vertex also plans to send a combination of VX-445 with teza... | AbbVie ( ABBV ) and Galapagos ( GLPG ) have also teamed up to make a triple-pill . Of its total sales, Vertex brought in $621 million in revenue from cystic fibrosis treatments, growing 37% year over year. Pending additional data in the first half of the year, Vertex also plans to send a combination of VX-445 with teza... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.